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dThe environment in which the field of cardiology finds itself
has been rapidly changing. This supplement, an expansion
of a report created for the Board of Trustees, is intended to
provide a timely snapshot of the socioeconomic, political,
and scientific aspects of this environment as it applies to
practice both in the United States and internationally. This
publication should assist healthcare professionals looking for
the most recent statistics on cardiovascular disease and the
risk factors that contribute to it, drug and device trends
affecting the industry, and how the practice of cardiology is
changing in the United States.
Global Burden of Cardiovascular Disease
Cardiovascular disease (CVD) currently accounts for nearly
half of noncommunicable diseases (NCDs). NCDs have over-
taken communicable diseases as the world’s major disease
burden, with CVD remaining the leading global cause of
death, accounting for 17.3 million deaths per year, a number
that is expected to grow to 23.6 million by 2030 (1,2).
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nd middle-income countries (LIMC) (Fig. 1), where 80%
f these deaths occur, usually at younger ages than in higher
ncome countries, and where the human and financial
esources to address them are most limited (2,3).
From 2011 to 2025, the projected cumulative economic
osses from all NCD is $7.28 trillion in LIMC. As displayed
n Figure 2, CVD accounts for nearly 50% of this projected
oss (4). Within LIMC, it is projected that reducing CVD
ortality by 10% would result in a $377 billion reduction in
conomic losses from 2011 to 2025 (5).
Economists project that the cost of not investing in
VD prevention and treatment could amount to as much
s $47 trillion worldwide in the next 25 years. This loss
s potentially avoidable because the prescribed World
ealth Organization (WHO) “best buy” interventions
nly cost $11 billion to $13 billion annually (6). The
onsequences will be more severe in developing countries,
iven that 80% of cardiovascular deaths occur in LMIC
ountries (7).
Cardiovascular disease is responsible for 10% of the
isability-adjusted life years (DALYs) lost in LMIC, and
or 18% of DALYs lost in high-income countries (8). The
ost of CVD to both families and society is related to both
loss of productivity and income of the person who has
VD and of their caregiver, who may have to stop working
o care for them. This economic loss is exacerbated in the
eveloping world where CVD affects a high proportion of
orking-age adults (9).
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country. The SHARE (Survey
of Health, Ageing, and Retire-
ment) in 11 European countries,
the HRS (Health Retirement
Survey) in the United States, and
the ELSA (English Longitudi-
nal Study of Aging) survey and
collect information regarding the
health of the aging population.
Table 1 synthesizes the studies
and displays comparisons of age-
adjusted self-reported prevalence of
heart disease and stroke by country.
It indicates that the United States
has the highest prevalence of heart
disease and stroke in both males and
females Table 1 (10).
CVD risk factors. OBESITY.
Globally, the prevalence of obe-
sity (body mass index [BMI]
30 kg/m2) doubled between
1980 and 2008, and it is esti-
mated that 2.8 million deaths
annually are caused by being
overweight (BMI 25 kg/m2) or
obese. In 2008, 10% of men and
14% of women globally were
obese compared with 5% of men
and 8% of women in 1980. The
Americas had the highest preva-
lence of overweight (62%) and obese
(26%) persons (1,11). Figure 3 and
Table 2 display the mean BMI
change by WHO region and
globally.
HYPERTENSION. Globally, some
40% of people over the age of 25
years have high blood pressure,
and the number of people with
elevated blood pressure (systolic
blood pressure 140 mm Hg or
diastolic blood pressure 90 mm
Hg) has increased from 600 million
n 1980 to a billion in 2008. The global hypertensive percentage
as improved over this period; however, some regions have
orsened in this respect. A decrease in the proportion of
opulations with high blood pressure was seen in the
estern Pacific, Europe, and the Americas, as shown in
igure 4 and Table 2 (12). Systolic blood pressure is
highest in LMIC. Globally, elevated blood pressure is
reported to cause 51% of stroke deaths and 45% of
coronary heart disease deaths (Table 2) (11).
DYSLIPIDEMIA. Mean total cholesterol levels around the
Abbreviations
and Acronyms
ACA  Affordable Care Act
ACC  American College of
Cardiology
ACO  Accountable Care
Organization
AHA  American Heart
Association
BMI  body mass index
CMS  Centers for
Medicare and Medicaid
Services
COI  conflict of interest
CVD  cardiovascular
disease
CVRN  Cardiovascular
Research Network
DALY  disability-adjusted
life year
DES  drug-eluting stent
EHR  electronic health
record
FDA  Food and Drug
Administration
FTE  full-time equivalent
HDL  high-density
lipoprotein
LDL  low-density
lipoprotein
LMIC  low- to middle-
income country
NCD  noncommunicable
disease
NIH  National Institutes
of Health
PCMH  patient-centered
medical home
PGPD  physician group
practice demonstration
TAVR  transcatheter
aortic valve replacement
YLL  years of lives lostworld are highest in high-income countries and have beendropping since 1980 throughout the world. The most
drastic decreases have been in high-income countries (5.62
to 5.19 mmol/l), but modest decreases in low-income
countries (4.46 to 4.20 mmol/l) and middle-income coun-
tries (4.91 to 4.7 mmol/l) have also been seen. Nevertheless,
some 39% of the global population still has elevated cho-
lesterol, as do more than one-half of those in higher income
countries (Fig. 5) (3).
SMOKING. Smoking rates among adults in the United
States have declined by more than one-half over the past 25
years, from 33.5% in 1980 to 15.1% in 2010—thought to be
the fourth lowest rate among OECD countries (countries
that signed the convention on Organization for Economic
Cooperation and Development) after Iceland, Sweden, and
Mexico. In contrast, at least 25% of residents living in
Greece, Chile, Ireland, Hungary, Estonia, Spain, and Tur-
key smoke cigarettes, according to the most recent data
(Table 3) (13).
Drivers of CVD. AGING AS A GLOBAL PHENOMENON.
Populations in the developed world have been aging for
decades due to rising life expectancy and falling birth rates.
The United Nations has calculated that the proportion of
the world’s population over the age of 65 years will more
than double by 2050, at which point approximately 1 billion
people around the world will be over the age of 65 years
(Fig. 6).
Problems associated with an aging population are ex-
pected to be particularly acute in wealthy, industrialized
countries such as Japan, Italy, and Germany, where 20% or
more of the population was 65 years of age or older in 2010.
In LIMC, the elderly are also expected to become an
increasingly large economic burden as they are expected to
Figure 1 Crude Data: Proportion of Deaths
Due to CVD by Country Income Level
CVD  cardiovascular disease. Source: Sinclair H. CVD Improvements and
Challenges of a Global Epidemic; MD Conference Express, November 2010.
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which the per capita income was under $10,000 in 2005
(14). In the absence of targeted policy measures, the aging
of the population is expected to lead to significant increases
in societal expenditures beginning around 2020 onward, the
largest proportion of it going to pensions, followed by
health and long-term care.
Life expectancy has been progressively increasing for
the last 50 years. Figure 7 shows life expectancy at birth
in 2009 (or nearest year available), and the years gained
since 1960.
URBANIZATION AND THE CVD RISK FACTOR BURDEN.
Living in a city—often a megacity (10 million people), of
which there are now 21 in the world—brings with it a
number of predictable hazards (15). Among those that
contribute to CVD are heavy environmental pollution, high
traffic, no sidewalks, and even the threat of violence outside
the home; these factors are major obstacles to physical
activity. Additionally, there are very few “green spaces,” or
open land for public use, contributing to the lack of exercise
and sedentary lifestyle (8).
Globalization and urbanization are key factors driving the
worldwide increase in obesity and diabetes mellitus (major
CVD risk factors), along with hypertension. With urban-
ization has come the global nutritional transition. This
transition includes an increase in consumption of animal-
source foods, edible oils, and sugars that has occurred in
high-income countries and is progressively occurring in
LMICs. This dietary change is influenced by the increasing
numbers of supermarkets in developing countries that tend
to serve processed foods higher in salt, fat, and added sugar.
Figure 2
Economic Loss (Trillions of US$ in 2008)
of Noncommunicable Diseases in Low- and
Middle-Income Countries, 2011 to 2025
Source: World Economic Forum and World Health Organization (5).In Latin America, for example, supermarkets’ share of foodsales increased from 15% to 60% over a 10-year period
(1990 to 2000). Another factor is the decreasing price of
animal source foods and grains (11). Low-income countries
often face a double burden of nutritional insufficiencies
among infants and children combined with greater access to
nutrition-poor food later in life. This has been found to
increase the risk for CVD later in life (11).
Migrating from rural to urban areas is shown to increase
blood pressure due to changing dietary patterns. Figure 8
shows that, on average, urban areas have a higher prevalence of
hypertension than rural areas (16). Finally, smoking rates are
also increasing among youth in several regions of the world due
to urbanization. Tobacco manufacturers aggressively market to
cities of LMIC. Unfortunately, children are most affected by
these campaigns, as they are more impressionable (8).
Mortality disparities. In comparison to high-income
countries, total years of life lost (YLL) to disease are more
than 4 times higher in LIMC and more than double in
middle-income countries. More than two-thirds of total
YLL are caused by communicable diseases, maternal and
perinatal conditions, as well as nutritional deficiencies. As
the burden of CVD risk factors increases in LMIC coun-
tries, the proportion of deaths due to CVD is projected to
increase, especially in LMIC countries, as displayed in
Figure 9. In contrast, the same causes account for only about
one-quarter of lives lost in middle-income countries and
fewer than 10% of lives lost in high-income countries
(Fig. 10) (11).
STROKE MORTALITY EXCEEDS ISCHEMIC HEART DISEASE
MORTALITY. CVD-associated stroke mortality exceeded
ischemic heart disease mortality in 74 WHO member
countries in a global analysis of WHO cause-specific mor-
tality data and World Bank national income data. China,
Africa, and South America had a disproportionately higher
burden of stroke (Fig. 11). Specifically, in the country with
Age-Adjusted Prevalence (% of Population)of Heart Disease and Stroke by Sex, 2004Table 1 Ag -Adjusted Prevalence (% of Population)of Heart Disease and Stroke by Sex, 2004
Country
Heart Disease Stroke
Males Females Males Females
Austria 12.2 7.3 5.2 3.5
Belgium 18.8 11.8 3.9 4.2
Denmark 10.8 7.6 6.5 4.6
France 19.3 9.8 3.7 3.5
Germany 14.3 9.3 5.6 3.1
Greece 14.9 10.7 4.1 3.5
Italy 12.7 9.1 3.8 2.5
Netherlands 14.7 8.9 5.0 4.8
Spain 11.4 10.0 2.4 1.8
Sweden 20.3 13.0 6.3 3.6
Switzerland 9.5 5.4 2.9 2.2
Total SHARE 15.4 9.9 4.5 3.5
United States (HRS) 26.4 19.7 6.6 5.5
England (HRS) 19.0 16.0 3.2 2.5HRS  Health Retirement Survey; SHARE  Survey of Health, Ageing, and Retirement.
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The Worldwide Environment of Cardiovascular Disease December 25, 2012:S1–S49the second largest excess, China, stroke mortality rate was
19.9% of total all-cause mortality compared with the 8.0%
attributed to ischemic heart disease. Conversely, Australia,
much of Europe, North America, and the Middle East
experienced a higher burden of ischemic heart disease
(Fig. 11) (17).
Global CVD initiatives. As CVD becomes a bigger health
concern in the developing world, the United Nations
political declaration on NCD resolved to reduce premature
death due to NCDs by 25%. To respond to the declaration,
a task force consisting of representatives from professional
societies (American College of Cardiology Foundation
[ACCF], American Heart Association (AHA), World
Heart Federation, European Heart Network, and European
Society of Cardiology) convened to establish risk factor
reduction targets. The targets to be reached by 2025 include
the following:
• 10% relative reduction in overall alcohol consumption
• 15% relative reduction in mean proportion of total
energy intake from saturated fatty acids
• Stop the increasing obesity prevalence
• 10% relative reduction in the prevalence of insufficient
activity
Figure 3 Change Over Time in Mean BMI by WHO Region, 200
AFR  African region; AMR  Americas region; BMI  body mass index; EMR  E
WHO  World Health Organization; WPR  West Pacific region. Source: World Hea
World Health Organization AbbreviationsTable 2 World Health Organization Abbreviations
Abbreviation WHO Region
AFR African Region
AMR Region of the Americas
SEAR South-East Asia Region
EUR European Region
EMR Eastern Mediterranean Region
WPR Western Pacific RegionnWHO  World Health Organization.• 25% relative reduction in prevalence of high blood
pressure
• 20% relative reduction in high total cholesterol
• 30% relative reduction in mean population intake of
salt
• 30% relative reduction in smoking prevalence (2).
The UnitedHealth Chronic Disease Initiative, together
with the National Heart, Lung, and Blood Institute, has
pledged $34 million over 5 years to support a network of
collaborating centers of excellence to help combat chronic
diseases, including CVD, in developing countries (18). A
esearch institution in each center within a developing
ountry is paired with at least 1 institution in a developed
ountry, and each center is responsible for carrying out
esearch tailored to local or regional needs (19).
A similar initiative is planned to improve medical educa-
ion and research capability in Sub-Saharan Africa. The
ational Institutes of Health and the President’s Emer-
ency Plan for AIDS relief collaborated to award funding to
he Medical Education Partnership Initiatives to address
hortages in specialized training. One clear need is cardiol-
gy training in Sub-Saharan Africa. For example, Zimba-
we has 3 trained cardiologists (2 adult cardiologists and 1
ediatric cardiologist). The main medical school in Zimba-
we received a Medical Education Partnership Initiatives–
ased grant (Cerebrovascular, Heart Failure, Rheumatic
eart Disease Interventions Strategy grant) to integrate
odern cardiovascular training within existing medical
chool education to improve health outcomes and improve
VD research capacity (20).
It should also be noted that access to up-to-date biomed-
cal research within the developing world is a key compo-
Mediterranean region; EUR  European region; SEAR  South-East Asia region;
anization (11).9
astern
lth Orgent to improving CVD care. The Health InterNetwork
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7,500 journal titles in the biomedical and health literature
to 105 academic institutions in developing countries. The
project is expected to continue until at least 2015 (21).
Changing Dynamics of Payment and Delivery
Economic pressure is causing the healthcare industry to
adopt new paradigms of care that service more people at
lower costs. The most recent national spending projections
from the Centers for Medicare and Medicaid Services
(CMS) estimate that U.S. healthcare spending will grow at
an average annual rate of 5.7% from 2011 through 2021,
rising from 17.9% of the gross domestic product ($2,495.8
billion) to 19.6% ($4,781.0 billion) (Fig. 12) (22,23).
Figure 4 Prevalence of Elevated Blood Pressure (SBP >140 m
Among Adults Over 25 Years by WHO Region, 1980 t
DBP  diastolic blood pressure; SBP  systolic blood pressure; other abbreviatio
Figure 5 Change Over Time in Mean Total Cholesterol by
Country Income Category
Green  high income; red  middle income; blue  low income. Source:
Anand et al. Stemming the global tsunami of cardiovascular disease. Lancet
2011 Feb 12.Mirroring the national trend of increasing costs, the
AHA’s recent projections show cardiovascular care cost
tripling from $272.5 billion in 2010 to an estimated $818.1
billion in 2030 (24). Figure 13 shows the projected direct
and indirect costs of all CVD, 2010 to 2030.
Between 2010 and 2030, real (2008$) total direct medical
costs of CVD are projected to triple, from $272.5 billion to
$818.1 billion (Table 4). Because it has a higher prevalence
than other CVD conditions, hypertension is the most
expensive component of CVD (24).
Real indirect costs for all CVDs are estimated to increase
from $171.7 billion in 2010 to $275.8 billion in 2030, an
increase of 61% (Table 4). Congestive heart disease has the
highest indirect cost and is expected to continue to account
for 40% of all CVD indirect costs (Table 4) (24).
It is important to note that these CVD projections were
made under the assumption that the status quo will be
maintained in CVD prevention and treatment trends (e.g.,
no increase in the use of generic drugs).
Roehrig and Rousseau (25) suggest that prior health
spending research has overly emphasized so-called treated
prevalence, namely, the number of people receiving treat-
ment for a given condition, rather than correctly accounting
for the effects of cost per case trends. Examining treated
prevalence, clinical prevalence (the number of people with a
given disease, treated or not) and cost per case across all
medical conditions between 1996 and 2006, they found
three-fourths of the increase in real per capita health
spending was attributable to growth in cost per case,
whereas treated prevalence accounted for about one-fourth
of spending growth. They conclude that most of the treated
prevalence effect is due to an increase in the share of eligible
people being treated rather than to an increase in clinical
or DBP >90 mm Hg)
8
in Figure 3. Source: World Health Organization (11).m Hg
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The Worldwide Environment of Cardiovascular Disease December 25, 2012:S1–S49health spending should focus more on reining in cost per
case (25). Table 5 shows the growth rate in real per capita
spending along with cost per case and treated prevalence
percentages for cardiovascular conditions between 1996
and 2006 (25).
Addressing rising costs, along with expanding coverage
and improving healthcare delivery, is a key focus of the
Affordable Care Act (ACA) approved by Congress in 2010
with key provisions, albeit modified concerning the expan-
sion of the Medicaid program, upheld in 2012. Table 6 lists
rovisions related to cost control enacted by the law (26).
Table 7 lists current CMS Innovation Center initiatives
29,30); Figure 14 shows percentage of total U.S. healthcare
pending by payment sources (2010).
are coordination. Addressing fragmented care through
Proportion of Population inOECD C untries Who Smoke, 2010*Table 3 Proportion of Population inOECD Countries Who Smoke, 2010*
Rank OECD Countries 2010
1 Greece 31.9
2 Chile 29.8
3 Ireland 29.0
4 Hungary 26.5
5 Estonia 26.2
5 Spain 26.2
7 Turkey 25.4
8 Czech Republic 24.6
9 Poland 23.8
10 France 23.3
11 Austria 23.2
12 Italy 23.1
13 Korea 22.9
14 Germany 21.9
15 United Kingdom 21.5
16 Netherlands 20.9
17 Belgium 20.5
18 Switzerland 20.4
19 Denmark 20.0
20 Japan 19.5
20 Slovak Republic 19.5
22 Finland 19.0
22 Norway 19.0
24 Slovenia 18.9
25 Israel 18.6
25 Portugal 18.6
27 New Zealand 18.1
28 Luxembourg 18.0
29 Canada 16.3
30 Australia 15.1
30 United States 15.1
32 Iceland 14.3
33 Sweden 14.0
34 Mexico 13.3
OECD average 21.1
*Or nearest available year. Source: OECD Health Data 2012 (13).
OECD  Organization for Economic Cooperation and Development.etter coordination is considered an approach that maymprove healthcare quality. Nonphysician professionals are
eing seen as a resource to alleviate pressure created by
hysician shortages. Various healthcare reform efforts are
nder way to develop teams of allied healthcare practitioners
ho will be able to provide team-based care for chronically
ll patients. Interdisciplinary teams are a key component to
rovide chronic disease management and transitional care
elivered in newer models of care such as accountable care
rganizations (ACOs).
The most significant model currently undergoing testing
nd development to understand the dynamics of team-based
are is the patient-centered medical home (PCMH)
31,32). The CMS is currently running the federally qual-
fied health center advanced primary care practice demon-
tration to determine whether the PCMH can improve
uality of care, promote better health, and lower costs. As of
ctober 2011, approximately 500 practices were enrolled in
he demonstration (33).
In an effort to alleviate potential obstacles in the creation
f PCMHs, the CMS Innovation Center has committed
unding to multiple PCMH efforts. These include pilot
rojects aimed at improving quality of care for vulnerable
opulations and implementation of the PCMH model in
edical settings. The CMS has designated these efforts
s the Health Care Innovation Awards and recently
istributed $122.6 million to 26 health centers in May
Figure 6 Elderly (Age 60 Years and Older),
as Percent of Population in 2010 and 2040
Red bars  2040; blue bars  2010. Source: UN Population Division,
World Population Prospects, 2010 Revision. United Nations, 2011.
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up to $1 billion to grantees that primarily serve Medicare,
Medicaid, and children under the Children’s Health
Insurance Program who will be transitioning to patient-
centered care and dispersed a second batch of funding in
June 2012 (34).
Along with the focus of the CMS on underserved
populations, the Innovation Center has helped fund a
multistate project for 12 Veterans Health Association-
affiliated hospitals. These hospitals have been given $20.75
million through the Health Care Innovation Awards en-
deavor to identify high-risk patients and to improve coor-
dination of care for these patients. Part of the care coordi-
nation process will include transitioning primary care
Figure 7 Life Expectancy at Birth, 2009 (or Nearest Year Avail
OECD  Organization for Economic Cooperation and Development. Source: OECD
OECD Publishing. Available at: http://www.oecd-ilibrary.org/economics/oecd-factbpractices within targeted communities to PCMHs. Fundingwill also support employee training and new positions that
will be specifically needed in transitions clinics (34).
Accountable care organizations. The ACO program,
which involves groups of hospitals, physicians, and other
clinicians that are responsible for the range of care of
specified groups of patients, requires a significant invest-
ment of resources by participating providers and has been
the most prominent of the reform efforts. Currently, a
pilot program is in place to test the ability of participating
institutions to facilitate coordination and cooperation to
improve quality of care and reduce costs (35). Participat-
ing institutions will be evaluated, and must perform in
the top 30th percentile for 70% of the 32 quality
measures established in the Medicare physician group
, and Years Gained Since 1960
OECD Factbook 2011–2012: Economic, Environmental and Social Statistics.
147364.able)
2012.
ook_18practice demonstration (PGPD) (Fig. 15) (36).
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model how physician groups could share in savings when
they spent less than projected. All 10 organizations that
participated in PGPD reached 30 of the 32 quality measures
after 5 years for patients with coronary artery disease,
congestive heart failure, hypertension, diabetes, and cancer
Figure 8 Difference in Prevalence of Hypertension in Urban and
Green bars  urban; lavender bars  rural. Source: Ibrahim and Damasceno (16)
Figure 9 Project Mortality Trends Globally by Income Category
Blue  injuries; taupe  other noncommunicable diseases; red  cancers; gold 
brown  other infectious diseases; and olive brown  human immunodeficiency v
resource settings. Available at: http://gm.stijlfabriek.com/issues/issue-10/cardioscreenings. On average, the PGPD organizations increased
their quality scores by 12 percentage points on heart failure,
6 percentage points on coronary heart disease, and 4
percentage points on hypertension (36). Subsequent analysis
determined that PGPD organizations saved an average of
$114 per Medicare beneficiary and $532 per dually eligible
l Regions
iovascular diseases; beige  maternal, perinatal, and nutritional conditions;
uberculosis, and malaria. Source: Agyemang C. Cardiovascular diseases in poor
ar-diseases-in-poor-resource-settings/. Accessed June 2012.Rura
.card
irus, t
vascul
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across practices, from a savings of $655 per capita to
spending $749 more per capita annually (37).
CMS quality initiatives. In addition to these programs
from the Innovation Center, CMS is implementing the
value-based purchasing, quality measure, and resource use
measurement programs in an effort to move away from the
current fee-for-service program (38).
The hospital value-based purchasing program under
CMS will begin in the 2013 fiscal year (39). The 2013 year
is considered a “dry run” and will generate reports for
hospitals on the basis of the quality measures to educate
them on the performance methodology but will not have
any financial consequences. Eligible hospitals will be eval-
Figure 10 Proportion of YLL Due to Premature Mortality by Bro
YLL  years of life lost. Source: World Health Organization. GBD 2004 Summary T
Figure 11 Geographic Distribution of Relative Mortality From S
Source: Kim and Johnston (17).uated on 12 clinical process of care and 8 hospital consumer
assessment of healthcare providers and systems measures,
with clinical care measures accounting for 70% of the score.
Measures are displayed in Tables 8 and 9 (40).
The Physician Compare website will soon publish physician
performance measures, much like Hospital Compare, a CMS-
funded website that publically reports hospital performance mea-
sures. There are no financial incentives tied to these performance
measures but they will be available for the public to review. The
physician quality reporting system examines quality measures for
services to Medicare beneficiaries and offers incentive payments to
high performers, utilizing data from claims, registries, electronic
health records (EHR), and the group practice reporting option
tool. The CMS intends for these data to be published on
ause and Country-Income Group, 2004
. 2008. Available at: http://www.who.int/evidence/bod. Accessed October 2012.
and Ischemic Heart Diseasead C
ablestroke
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there will be penalties for physicians who do not report to
the website (41).
The physicians resource use measurement and reporting
program will be incorporated into the value-based payment
modifier program by providing individualized feedback to
providers, including how they compare to their peers. The
CMS incorporates cost and quality information when cal-
culating potential reimbursements. The CMS will apply a
value-based payment modifier based on performance mea-
sures beginning in 2015. Beginning in 2017, the value-
based payment modifier scheme will be applied to most
physicians who submit claims under the Medicare physician
fee-for-service schedule (42).
Figure 12 National Healthcare Expenditure Projections by Expe
Red  total health expenditure; dark brown  hospital care; light brown  physician
dark red  government administration. Source: Centers for Medicare and Medicai
Figure 13 Projected Direct and Indirect Costs of CVD, 2010 to
Red  direct medical costs; brown  indirect medical costs. CVD  cardiovasculMeasure Application Partnership. The Department of
Health and Human Services has contracted with the Na-
tional Quality Forum, a consensus-based organization, to
convene Measure Application Partnership as the body that
helps coordinate and provide upstream recommendations
on performance measure use. Utilizing what is termed
“families of measures,” this approach is intended to help
move the field toward a more patient-driven, integrated,
and synchronized approach to measuring healthcare perfor-
mance by giving implementers a pre-screened group of
measures carefully selected to work cohesively in pursuit of
specific healthcare improvement goals (43).
For the first series of recommendations, Measure Appli-
cation Partnership reviewed 676 measures across the topics
re Type, 2011 to 2021
linical services; gray  prescription drugs; black  net cost of insurance;
ices (22).
0
ase. Source: Heidenreich et al. (24).nditu
and c
d Serv203
ar dise
ke, and
I
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diabetes; and recommended 55 safety, 62 care coordination,
37 cardiovascular, and 13 diabetes measures for inclusion in
the measure families (44). The cardiovascular measures are
provided in Table 10.
Cardiovascular procedure trends. In 2010, an estimated
7.5 million inpatient cardiovascular procedures were per-
formed in the United States. Of these procedures, 4.3
million were performed on males and 3.1 million on females
(45). Figure 16 displays a detailed breakdown of inpatient
procedures from 1993 to 2010 from the Nationwide Inpa-
tient Sample. Figure 17 displays the trends of cardiovascular
procedures from 2007 to 2010 based on the National
Hospital Discharge Survey. Figure 18 displays a decade of
procedure trends for all cardiac stents. From 2000 to the
peak in 2006, the number of cardiac stent procedures
increased by 52%. The number of stent procedures subse-
quently declined by 40% from 2006 to 2010.
Medicare data from 1999 to 2008 showed the number of
procedures done in cardiovascular care in the United States
Projected Direct Medical Costs and Indirect (LostCosts of Cardiovascular Disease, 2010 o 203Table 4 Pr jected Direct Medical Costs andCosts of Cardiovascular Disease,
2010
Direct medical cost
All cardiovascular cisease* 272.5
Coronary heart disease 35.7
Heart failure 24.7
Hypertension 69.9
Hypertension as risk factor 130.7
Stroke 28.3
Indirect medical cost
All cardiovascular disease* 171.7
Coronary heart disease 73.2
Heart failure 9.7
Hypertension 23.6
Hypertension as risk factor 25.4
Stroke 25.6
*Includes hypertension, coronary heart disease, heart failure, stro
pulmonary heart disease, and other or ill-defined heart disease.
Decomposition of Real Per Capita Health Spending Growth, 1996 tTable 5 Decomposition of Real Per Capita Health Spending Gro
Ex
Category/Conditiona
Nominal Spending
(Billions of Dollars)
Real Per Capi
Spending Growth1996 2006
Circulatory system 115.9 200.4 2.3
Heart conditions 65.3 93.3 0.3
Coronary heart disease 46.3 59.8 0.7
Congestive heart failure 7.1 15.5 4.6
Dysrhythmias 9.9 14.0 0.2
Cerebrovascular disease 16.1 18.8 1.7
Hypertension 15.2 38.7 6.3
Hyperlipidemiab 4.5 22.9 14.0
aSource: Roehrig and Rousseau (25). Medical conditions are not all-inclusive, so expenditures by conditi
nternational Classification of Diseases-Ninth Revision (ICD-9), but is included under circulatory here.is growing simultaneously with the rising cost to treat
cardiovascular diseases (24). From 1999 to 2009, the num-
ber of inpatient cardiovascular procedures increased by 22%
(based on the National Center for Health Statistics data)
(46). Among Medicare beneficiaries, it was found that
invasive procedures (coronary, peripheral vascular, and elec-
trophysiological procedures) did not contribute substantially
to the increase of cardiovascular procedures and are, in fact,
decreasing. Figure 19 displays the trends of growth of services
provided by categories of services. Among noninvasive proce-
dures, nuclear stress testing increased 3.2-fold, peripheral
vascular ultrasonography increased 2.8-fold, event monitoring
grew 2.6-fold, transthoracic and transesophageal echocardiog-
raphy grew 90% and 70%, respectively, and electrocardiogra-
phy increased 28% (47).
Noninvasive procedures (electrophysiological monitoring,
resting imaging, transesophageal echocardiography, and
stress testing) grew 70% from 1999 to 2008 (47). However,
studies indicate the growth rate of noninvasive diagnostic
imaging utilization leveled off from 2005 to 2008. From
uctivity)nited Statesct (Lost Productivity)
to 2030, United States
5 2020 2025 2030
0 470.3 621.6 818.1
8 61.4 81.1 106.4
4 42.9 57.5 77.7
4 119.1 155.0 200.3
4 222.5 293.6 389.0
0 51.3 70.0 95.6
7 220.0 246.1 275.8
8 92.0 101.5 112.3
3 13.0 15.1 17.4
2 31.0 35.1 39.8
3 33.3 37.8 42.8
7 34.0 38.9 44.4
cardiac dysrhythmias, rheumatic heart disease, cardiomyopathy,
061996 to 2006
1
Component Subcomponent
Cost Per
Case (%)
Treated
Prevalence (%)
Clinical, at 2%
Ceiling (%)
Proportion
Treated (%)
0.4 1.8 0.3 1.6
0.1 0.5 0.1 0.4
0.0 0.7 0.7 0.0
0.4 4.2 2.0 2.2
2.0 2.2 1.5 0.7
0.2 1.8 2.6 0.7
1.8 4.5 2.0 2.5
1.1 12.9 2.0 10.9
bProd0, UIndire
2010
201
358.
46.
32.
91.
170.
38.
195.
82.
11.
27.
29.
29.o 20wth,
hibit
ta
(%)on sum to less than category totals. Hyperlipidemia is mapped to the endocrine chapter in the
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Cost Containment Provision
Administrative simplification ● Simplify health insurance administration by adopting a single set of operating rules for eligibility verification and claims status (rules
adopted July 1, 2011; effective January 1, 2013), electronic funds transfers and healthcare payment and remittance (rules adopted July 1,
2012; effective January 1, 2014), and health claims or equivalent encounter information, enrollment and disenrollment in a health plan,
health plan premium payments, and referral certification and authorization (rules adopted July 1, 2014; effective January 1, 2016). Health
plans must document compliance with these standards or face a penalty of no more than $1 per covered life. (Effective April 1, 2014.)
Medicare ● Restructure payments to Medicare Advantage (MA) plans by setting payments to different percentages of Medicare fee-for-service (FFS) rates,
with higher payments for areas with low FFS rates and lower payments (95% of FFS) for areas with high FFS rates. Phase in revised payments
over 3 years beginning in 2011, for plans in most areas, with payments phased in over longer periods (4 years and 6 years) for plans in other
areas. Provide bonuses to plans receiving 4 or more stars, based on the current 5-star quality rating system for MA plans, beginning in 2012;
qualifying plans in qualifying areas receive double bonuses. Modify rebate system with rebates allocated based on a plan’s quality rating. Phase
in adjustments to plan payments for coding practices related to the health status of enrollees, with adjustments equaling 5.7% by 2019. Cap
total payments, including bonuses, at current payment levels. Require MA plans to remit partial payments to the Secretary if the plan has a
medical loss ratio of 85%, beginning 2014. Require the Secretary to suspend plan enrollment for 3 years if the medical loss ratio is85% for
2 consecutive years and to terminate the plan contract if the medical loss ratio is 85% for 5 consecutive years.
● Reduce annual market basket updates for inpatient hospital, home health, skilled nursing facility, hospice, and other Medicare providers,
and adjust for productivity. (Effective dates vary.)
● Freeze the threshold for income-related Medicare Part B premiums for 2011 through 2019, and reduce the Medicare Part D premium
subsidy for those with incomes $85,000/individual and $170,000/couple. (Effective January 1, 2011.)
● Establish an Independent Payment Advisory Board composed of 15 members to submit legislative proposals containing recommendations to
reduce the per capita rate of growth in Medicare spending if spending exceeds a target growth rate. Beginning April 2013, require the Chief
Actuary of the Centers for Medicare and Medicaid Services (CMS) to project whether Medicare per capita spending exceeds the average of
Consortium for Performance Improvement (CPI)-U and CPI-M, based on a 5-year period ending that year. If so, beginning January 15, 2014, the
Board will submit recommendations to achieve reductions in Medicare spending. Beginning January 2018, the target is modified such that the
Board submits recommendations if Medicare per capita spending exceeds gross domestic product per capita plus 1%. The Board will submit
proposals to the President and Congress for immediate consideration. The Board is prohibited from submitting proposals that would ration care,
increase revenues, or change benefits, eligibility, or Medicare beneficiary cost sharing (including Parts A and B premiums), or would result in a
change in the beneficiary premium percentage or low-income subsidies under Part D. Hospitals and hospices (through 2019) and clinical
laboratories (for 1 year) will not be subject to cost reductions proposed by the Board. The Board must also submit recommendations every other
year to slow the growth in national health expenditures while preserving quality of care by January 1, 2015. The Secretary of Health and Human
Services (HHS) is directed to implement the Board’s proposals automatically unless Congress affirmatively acts to alter the Board’s proposals or
to discontinue the automatic implementation of such proposals (27).
● Reduce Medicare Disproportionate Share Hospital (DSH) payments initially by 75% and subsequently increase payments based on the
percent of the population uninsured and the amount of uncompensated care provided. (Effective fiscal year 2014.)
● Eliminate the Medicare Improvement Fund. (Effective upon enactment.)
● Allow providers organized as an accountable care organization (ACO) that voluntarily meet quality thresholds to share in the cost savings
they achieve for the Medicare program. To qualify as an ACO, organizations must agree to be accountable for the overall care of their
Medicare beneficiaries, have adequate participation of primary care physicians, define processes to promote evidence-based medicine,
report on quality and costs, and coordinate care. (Shared savings program established January 1, 2012.)
● Create an Innovation Center within the CMS to test, evaluate, and expand in Medicare, Medicaid, and CHIP different payment structures
and methodologies to reduce program expenditures while maintaining or improving quality of care (see Table 7). Payment reform models
that improve quality and reduce the rate of cost growth could be expanded throughout the Medicare, Medicaid, and CHIP programs.
(Effective January 1, 2011.)
● Reduce Medicare payments that would otherwise be made to hospitals by specified percentages to account for excess (preventable)
hospital readmissions. (Effective October 1, 2012.)
Medicaid ● Reduce Medicare payments to certain hospitals for hospital-acquired conditions by 1%. (Effective fiscal year 2015.)
● Increase the Medicaid drug rebate percentage for brand name drugs to 23.1 (except the rebate for clotting factors and drugs approved
exclusively for pediatric use increases to 17.1%); increase the Medicaid rebate for non-innovator, multiple source drugs to 13% of average
manufacturer price. (Effective January 1, 2010.) Extend the drug rebate to Medicaid managed care plans. (Effective upon enactment.)
● Reduce aggregate Medicaid DSH allotments by $.5 billion in 2014, $.6 billion in 2015, $.6 billion in 2016, $1.8 billion in 2017, $5 billion in
2018, $5.6 billion in 2019, and $4 billion in 2020. Require the Secretary to develop a methodology to distribute the DSH reductions in a manner
that imposes the largest reduction in DSH allotments for states with the lowest percentage of uninsured or those that do not target DSH
payments, imposes smaller reductions for low-DSH states, and accounts for DSH allotments used for 1115 waivers. (Effective October 1, 2011.)
● Prohibit federal payments to states for Medicaid services related to healthcare acquired conditions. (Effective July 1, 2011.)
Prescription drugs ● Authorize the Food and Drug Administration to approve generic versions of biologic drugs and grant biologics manufacturers 12 years of
exclusive use before generics can be developed. (Effective upon enactment.)
Waste, fraud, and abuse ● Reduce aggregate Medicaid DSH allotments by $.5 billion in 2014, $.6 billion in 2015, $.6 billion in 2016, $1.8 billion in 2017, $5 billion in
2018, $5.6 billion in 2019, and $4 billion in 2020. Require the Secretary to develop a methodology to distribute the DSH reductions in a manner
that imposes the largest reduction in DSH allotments for states with the lowest percentage of uninsured or those that do not target DSH
payments, imposes smaller reductions for low-DSH states, and accounts for DSH allotments used for 1115 waivers. (Effective October 1, 2011.)
● Reduce waste, fraud, and abuse in public programs by allowing provider screening, enhanced oversight periods for new providers and suppliers,
including a 90-day period of enhanced oversight for initial claims of DME suppliers, and enrollment moratoria in areas identified as being at
elevated risk of fraud in all public programs, and by requiring Medicare and Medicaid program providers and suppliers to establish compliance
programs. Develop a database to capture and share data across federal and state programs, increase penalties for submitting false claims,
strengthen standards for community mental health centers, and increase funding for antifraud activities. (Effective dates vary.)Data for 2010 show the Centers for Medicare and Medicaid Services (CMS) as the largest single payer entity in the United States, responsible for almost 40% of NHE (Fig. 14) (28). Due to its large share
of the payer market, reform efforts implemented by CMS often have the most significant effects on care delivery models.
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declined to 1.4% from 2005 to 2008 (48). Further evidence
indicates that among Medicare beneficiaries volume of
imaging services has decreased in 2010 and 2011 (49).
Preventable hospital readmissions have been identified as
a significant driver of costs, estimated at $25 billion annually
(50). An estimated 20% of Medicare beneficiaries are
readmitted to the hospital within 30 days and 34% within
90 days, costing an estimated $17.5 billion annually (51,52).
Effective October 1, 2012, CMS implemented the Read-
missions Reduction Program, reducing payments to hospi-
tals with excess readmissions (53).
Comparative effectiveness research. Comparative effec-
tiveness research, a controversial topic in the industry, is a
main focus of the Patient-Centered Outcomes Research
Current Centers for Medicare and Medicaid Innovation Center InitiaTable 7 Current Centers for Medicare and Medicaid Innovation
Initiative
Initiative Start
Date Length
Primary care transformation
Comprehensive primary care
initiative demonstration
Fall 2012 4 yrs
Federally qualified health center
(FQHC) advanced primary care
practice demonstration
November 2011 3 yrs
Multipayer advanced primary care
practice demonstration
Phase-in begins
July 2011
3 yrs
Independence at home Summer 2012 3 yrs
Bundled payments for care improvement
Bundled payment for care improvement
initiative
2012 3 yrs
Accountable care organizations
Pioneer accountable care
organization model initiative
January 2012 3 yrs (potential
2-yr extension)
Accelerated development learning
sessions
June 2011 3 sessions
completed
Advanced payment accountable care
organization model initiative
April or July 2012 Payments end
June 2014
Physician group practice transition
demonstration
January 2012 Up to 3 yrs
Medicare-Medicaid enrollees
State demonstrations to integrate
care for Medicare-Medicaid
enrollees
April/May 2011 18 months with
extension
option
Financial alignment model
demonstrations
January 2013 3 yrs
Capacity to spread innovation
Partnership for patients April 2011 Ongoing
Innovation advisors program January 2012 Ongoing
Health care innovation challenge May 2012 3 yrs
Other
Medicaid emergency psychiatric
demonstration
Spring 2012 3 yrs
Medicaid incentives for prevention of
chronic diseases program
September 2011 5 yrs
*Funding based on other statutory authorities. Sources: Centers for Medicare and Medicaid Innova
doing, CMS, 2012.
TBD  to be determined.Institute. The Institute has committed approximately $120million of research funding through the end of 2012 to
support its initial research agenda (see the following list), in
addition to the $30 million awarded for pilot projects. As of
April 2012, 50 pilot projects were approved to receive
funding for up to 2 years, at a total of approximately $15
million per year (54).
The Patient-Centered Outcomes Research Institute’s
Five Priorities are as follows:
1. Assessment of prevention, diagnosis, and treatment op-
tions: comparing the effectiveness and safety of alterna-
tive prevention, diagnosis, and treatment options to see
which ones work best for different people with a partic-
ular health problem.
2. Improving healthcare systems: comparing health system-
ter Initiatives
articipants/Locations Total Funding
Number of Beneficiaries
Affected
rimary care practices in
CO, NJ, NY, OH, OK, OR
$322 million 313,00 Medicare
QHCs in 44 states $49.7 million 195,000 Medicare
E, MI, MN, NY, PA, RI, VT $283 million* 332,000 Medicare
ependent practices
3 consortia
$15 million* 10,000 Medicare
$118 million Not available
Os $77 million 860,000 Medicare
ble to all developing or
ting ACOs
$1.5 million Not available
ian-based and rural ACOs
he shared savings program
$175 million 650,000 Medicare
up practices initially,
itched to pioneer ACO
del
$500,000 (administrative
cost)*
87,700 Medicare
, CT, MA, MI, MN, NY, NC,
OR, SC, TN, VT, WA, WI
$15 million Not available
tes and DC have submitted
ers of intent
TBD 2 million Medicare-
Medicaid enrollees
spital engagement
works
$500 million Not available
dvisors $5.9 million Not available
tes $1 billion Not available
tes and DC $75 million* Not available
tes $100 million* Not available
ne year of innovation, CMS, 2012; and Centers for Medicare and Medicaid Innovation: what we’retivesCen
P
500 p
AR,
500 F
NC, M
15 ind
and
TBD
32 AC
Availa
exis
Physic
in t
10 gro
3 sw
mo
CA, CO
OK,
38 sta
lett
26 ho
net
200 a
50 sta
11 sta
10 sta
tion: olevel approaches to improving access, supporting patient
3S14 Laslett et al. JACC Vol. 60 Suppl S, No. 25, 2012
The Worldwide Environment of Cardiovascular Disease December 25, 2012:S1–S49self-care, innovative use of health information technol-
ogy, coordinating care for complex conditions, and
deploying workforce effectively.
Figure 14 Percentage of Total U.S. Healthcare Spending by Pa
Source: California Health Care Foundation. U.S. Healthcare Spending: Health Care
Figure 15 Physician Group Practice Demonstration Quality Me
Ace  angiotensin-converting enzyme; Exam  examination; Hb  hemoglobin; HF
Dept Health and Human Services. Medicare Physician Group Practice Demonstrati
care physician pay-for-performance demonstration, July 2011.. Communication and dissemination research: comparing
approaches to providing comparative effectiveness re-
search information, empowering people to ask for and
t Sources, 2010
101. Oakland, CA: California Health Care Foundation, 2012.
s
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making between patients and their providers.
. Addressing disparities: identifying potential differences
in prevention, diagnosis or treatment effectiveness, or
preferred clinical outcomes across patient populations
and the health care required to achieve best outcomes in
each population.
. Accelerating patient-centered outcomes research and
methodological research: improving the nation’s capacity
to conduct patient-centered outcomes research, by build-
ing data infrastructure, improving analytic methods, and
training researchers, patients, and other stake holders to
participate in this research (55).
ealth information technology. The federal government
as committed in excess of $27 billion over 10 years to
ncrease the use of EHR. Many physicians and practices
gree that EHR can improve clinical decision making and
atient outcomes and are already making the transition from
aper to EHR use in their practice (56).
MEANINGFUL USE CRITERIA. The use of EHR is encour-
ged by CMS through an incentive program that provides
nancial benefits for physicians and care centers that show
meaningful use” of EHR. The primary component of
eaningful use is utilizing EHR in a meaningful man-
Clinical Process of Care UnderValue-Based Purchasing Reimbursement ModelTable 8 Clinical Process of Care UnderValue-Based Purchasing Reimbursement Model
Acute myocardial infarction
AMI-7a Fibrinolytic therapy received within 30 min
of hospital arrival
AMI-8 Primary PCI received within 90 min of hospital arrival
Heart failure
HF-1 Discharge instructions
Pneumonia
PN-3b Blood cultures performed in the ED prior to initial
antibiotic received in hospital
PN-6 Initial antibiotic selection for CAP in
immunocompetent patient
Health care associated infections
SCIP-Inf-1 Prophylactic antibiotic received within 1 h
SCIP-Inf-2 Prophylactic antiobiotic selection for surgical patient
SCIP-Inf-3 Prophylactic antibiotics discontinued within 24 h
after surgery
SCIP-Inf-4 Cardiac surgery patients with controlled 6 AM
post-operative serum glucose
Surgeries
SCIP-Card-2 Surgery patients on a beta-blocker prior to arrival
that received beta-blocker during the perioperative
period
SCIP-VTE-1 Surgery patients with recommended venous
thromboembolism prophylaxis ordered
SCIP-VTE-2 Surgery patients who received appropriate venous
thromboembolism prophylaxis within 24 h
Source: Centers for Medicare and Medicaid Services (40).
AMI  acute myocardial infarction; Card  cardiac; ED  emergency department; HF  heart
failure; Inf  infection; PCI  percutaneous coronary intervention; PN  pneumonia; VTE  venous
thromboembolism.er—in other words, to exchange health information elec-ronically to improve care and to submit quality measures.
etween 2011 and 2016, each clinician who is eligible under
he meaningful use criteria can receive up to $63,750 in total
ayments for demonstrating meaningful EHR use and may
e eligible for both Medicare and Medicaid incentives as
ell (57).
One aspect of the meaningful use criteria for EHR
ncentives (both Medicare and Medicaid) is participation in
linical quality measures. Clinical quality measures assess
bservations, processes, experience, treatment, and out-
omes of patient care. Professionals eligible for EHR
ncentives are required to report 6 clinical quality measures,
hereas hospitals and acute care centers are required to
eport 15 (57).
Hospitals and other providers have until 2015 to utilize
lectronic medical records before they incur penalties
58). Nearly 46% of clinical sites, ranging from solo
ractices to hospitals, had adopted EHR as of January
012 (59). Conversely, only 58% of eligible hospitals and
5% of eligible physicians have enrolled in the meaning-
ul use incentive program, and 16% of eligible hospitals
nd 6% of eligible professions have received payments
hus far (58).
It is admittedly more difficult for smaller practices to
dopt EHR and be eligible for meaningful use incentives.
easons for this vary, but include the financial cost of
mplementing EHR, concerns about what the return of
nvestment will be once adopted, and the fact that EHR
echnology may become obsolete. It is, therefore, somewhat
urprising that only 21% of small practices reported resis-
ance to EHR adoption compared with 32% of practices
ith more than 11 physicians (60). Figure 20 displays the
isparities in EHR adoption as of 2011 (61).
Certain inpatient providers are not eligible for meaning-
ul use incentives. These include long-term care facilities,
ehabilitation hospitals, and psychiatric hospitals, all of
hich are less likely to adopt EHRs. One study found that
nly 6% of long-term acute care hospitals, 4% of rehabili-
ation hospitals, and 2% of psychiatric hospitals had mini-
um basic EHRs, and obstacles for providers to take
dvantage of the meaningful use incentive continue (62).
There is a great need for advanced health information
echnology implementation to achieve quality improvement
nd patient-centered care. As investigators of a Health
Patient Experience of Care Measures UnderV lu -Based Pur hasing Reimbursement ModelTable 9 Patient Experience of Care M asures UnderValue-Based Purchasing Reimbursement Model
1. Nurse communication
2. Doctor communication
3. Hospital staff responsiveness
4. Pain management
5. Medicine communication
6. Hospital cleanliness and quietness
7. Discharge information
8. Overall hospital ratingSource: Centers for Medicare and Medicaid Services (40).
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otential avenue by which to improve HIT competencies
nd increasing EHR adoption; if offered, continuing med-
cal education could allow more clinicians to be eligible for
eaningful use incentives over the next 10 years.
orkforce
ncreasing demand, changing business requirements, and pro-
Chronic Cardiovascular Conditions Family of Measures by Level ofTable 10 Chronic Cardiovascular Conditions Family of Measure
Primary Prevention
Outpatient Inpatient
Clinician group/
individual
Smoking cessation/tobacco use
(0028, 1406)*
Smoking cessation/
tobacco use
Lifestyle management—
weight/obesity (0024, 0421)*
Blood pressure control (0018)*
Lipid control
Lifestyle management—diet/nutrition
Lifestyle management—activity/
exercise
Cardiometabolic risk
Resource use (1598 and 1604)*
Provider/facility Smoking cessation/tobacco use Smoking cessation/
tobacco use
(1651, 1654)*
Lipid control
Lifestyle management—
weight/obesity
Lifestyle management—
diet/nutrition
Lifestyle management—
activity/exercise
Cardiometabolic risk
System Lifestyle management—weight/obesity (0024)*
Blood pressure control (0018)*
Smoking cessation/tobacco use
Lipid control
Blood pressure control
Screening
Lifestyle management—diet/nutrition
Lifestyle management—activity/exercise
Cardiometabolic risk
Resource use (1598 and 1604)*
Community Smoking cessation/tobacco use (1406, 1651, 1654)*
Lifestyle management—weight/obesity (0024, 0421)*
Blood pressure control (0018)*
Cardiometabolic risk
Lipid control
Lifestyle management—diet/nutrition
Lifestyle management—activity/exercise
Resource use (1598 and 1604)*
*High-leverage opportunities represent areas where the task force has identified measures to popu
ACE  angiotensin-converting enzyme; Afib  afibrillation; ARB  angiotensin-receptor blockerider restructuring have created significant concerns regarding whe capacity of the current and future medical workforce to
eet the needs of patients. Recent physician surveys found that
early one-third intend to retire in the next 10 years, and more
han three-quarters of physicians are somewhat pessimistic or
ery pessimistic about the future of the medical profession
63,64).
hysician workforce. In 2010, there were 258.7 active
hysicians per 100,000 U.S. residents and 219.5 physicians
sis Along the Patient-Focused Episode of CareLevel of Analysis Along the Patient-Focused Episode of Care
valuation and Initial Management
Follow-Up Care
Outpatientutpatient Inpatient
nctional status HF functional status Afib medications— anticoagulation
(1525)*
HF medications—ACE/ARB (0081)*
HF medications—beta-blocker (0083)*
HF medications—ACE/ARB, beta-blocker
persistence
nctional status HF functional status HF medications—beta-blocker (0083)*
lity—HF
229)*
Mortality—HF
(0229)*
HF medications—ACE/ARB, beta-blocker
persistence
HF early identification of
decompensated HF
lity HF medications—ACE/ARB, beta-blocker
persistencenctional status
lity HF medications—ACE/ARB, beta-blocker
persistencenctional status
e family; other entries are considered gaps. For additional detail, see National Quality Forum (44).
heart failure.Analys by
E
O
HF fu
HF fu
Morta
(0
Morta
HF fu
Morta
HF fuho were active in patient care per 100,000 residents in the
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was highly variable between states, with a surfeit of physi-
cians being clustered in northeastern states in comparison to
the southeast (Table 11, Fig. 21).
On the basis of projections made by the Association of
American Medical Colleges, it is expected that the United
States will be short 91,500 to 130,600 physicians by 2025
(Fig. 22) (66).
Figure 16 Trends in Number of Cardiovascular Procedures, Uni
Note: In-hospital procedures only. CABG  coronary artery bypass graft surgery; PT
Healthcare Research and Quality. Center for Delivery, Organization, and Markets, H
Figure 17 Number of Discharges From Short-Stay Hospitals by Pr
CABG  coronary artery bypass graft surgery. Source: Centers for Disease Control
tals by procedure category: United States, 2007–2010. Available at: http://www.c
June 2012.The projections from Figure 22 reflect the current supply
and utilization of physicians and disease burdens applied to
future population trends. Assumptions in this model are
based on speculated utilization shifts due to the ACA.
These include increased physician utilization rates for peo-
ple over 45 years of age; decreased working hours of
physicians due to sex and generational trends; growth in
medical school graduates; and growth in productivity
tates, 1993 to 2010
percutaneous transluminal coronary angioplasty. Source: Agency for
care Cost and Utilization Project: Nationwide Inpatient Sample, 1993–2010.
re Category, 2007 to 2010, National Hospital Discharge Survey
revention. Number of all-listed procedures for discharges from short-stay hospi-
/nchs/data/nhds/4procedures/2010pro4_numberproceduresex.pdf. Accessedted S
CA 
ealthocedu
and P
dc.gov
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by authorizing the following:
• $250 million to support training of 16,000 new
primary care providers for fiscal years 2010 to 2014;
• $320 million over the same period to increase the
number of primary care residency positions, to
expand training opportunities for physician assis-
tants and nurse practitioners, and to create nurse-
managed health clinics;
• A 10% bonus for fiscal years 2011 to 2016 under the
Medicare fee schedule for family physicians, inter-
Figure 18 Trends in Cardiac Stents, United States, 2000 to 20
Note: In-hospital procedures only. Source: Agency for Healthcare Research and Qu
Healthcare Cost and Utilization Project: Nationwide Inpatient Sample, 2000–2010
Figure 19 Trends of Growth of Services Provided by Categories
Source: Andrus and Welch (47).nists, geriatricians, nurse practitioners, and physi-
cian assistants—aimed at narrowing the income
gap between primary care providers and medical
specialists;
• A requirement that states increase Medicaid pay-
ment rates to Medicare levels in fiscal years 2013
and 2014 for providers who deliver certain primary
care services; and
• creation of a 15-member Health Care Workforce
Commission, designed to assess the demand for
healthcare workers and whether it is being met (67).
enter for Delivery, Organization, and Markets,
. Available at: http://hcupnet.ahrq.gov/. Accessed October 2012.
ervices, 1999 to 200810
ality. C
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in 2012 noted the following:
• More than three-quarters of physicians—77.4%—are
somewhat pessimistic or very pessimistic about the
future of the medical profession.
• More than 84% of physicians agree that the medical
profession is in decline.
• The majority of physicians—57.9%—would not rec-
ommend medicine as a career to their children or to
other young people.
• More than one-third of physicians would not choose
medicine if they had their careers to do over.
• Physicians are working 5.9% fewer hours than
they did in 2008, resulting in a loss of 44,250
full-time equivalents (FTEs) from the physician
workforce.
Figure 20 Percentage of EHR Systems Adoption, by Physician
EHR  electronic health record; HMO  health maintenance organization. Source:
Highest 5 Rates and Lowest 5 Rates ofActive Physicians per 100,000 Populati n in 2010Table 11 Highest 5 Rates and Lowest 5 Rates ofActive Physicians per 100,000 Population in 2010
States With
Highest Rates
States With
Lowest Rates
Massachusetts 415.5 Utah 197.8
Maryland 368.7 Wyoming 193.0
New York 347.5 Arkansas 189.6
Rhode Island 332.6 Idaho 184.2
Connecticut 331.1 Mississippi 176.4
Data source: AAMC Center for Workforce Studies. 2011 State Physician Workforce Data
Book, November 2011. Available at: https://www.aamc.org/download/263512/data/
statedata2011.pdf.• Physicians are seeing 16.6% fewer patients per day
than they did in 2008, a decline that could lead to
tens of millions of fewer patients seen per year.
• Physicians spend more than 22% of their time on
nonclinical paperwork, resulting in a loss of some
165,000 FTEs.
• More than 60% of physicians would retire today if they
had the means.
• Physicians are not uniform in their opinions—
younger physicians, female physicians, employed
physicians, and primary care physicians are generally
more positive about their profession than are older
physicians, male physicians, practice owners, and
specialists.
• More than 52% of physicians have limited the access
Medicare patients have to their practices or are plan-
ning to do so.
• More than 26% of physicians have closed their prac-
tices to Medicaid patients.
• In the next 1 to 3 years, more than 50% of physicians
plan to cut back on patients, work part-time, switch to
concierge medicine, retire, or take other steps that
would reduce patient access to their services.
• More than 59% of physicians indicate passage of the
ACA (i.e., “health reform”) has made them less
positive about the future of health care in America.
• More than 82% of physicians believe doctors have little
Practice Size, Ownership, and Specialty, 2011
om et al. (61).Age,
Jamoability to change the healthcare system.
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system will be or how they will fit into it 3 to 5 years
from now.
• More than 62% of physicians said ACOs are either
unlikely to increase healthcare quality and decrease
costs or that any quality/cost gains will not be worth
the effort.
• Physicians are divided on the efficacy of medical
homes, and many (37.9%) remain uncertain about
their structure and purpose.
• More than 47% have significant concerns that EHR
poses a risk to patient privacy.
• More than 62% of physicians estimate they provide
$25,000 each year in uncompensated care (64).
Jackson Healthcare’s 2012 physician survey (n  2,218)
found that the majority of physicians surveyed (84%) expect
Figure 21 Total Active Physicians per 100,000 Population, 20
Source: Association of American Medical Colleges. Center for Workforce Studies:
Available at: https://www.aamc.org/download/263512/data/statedata2011.pdf.
Figure 22 Projected Supply and Demand, FTE Physicians Activ
FTE  full-time equivalent. 2Primary care includes physicians whose specialty is lis
3“Non-primary care” includes physicians in all specialties except primary care spe
The Impact of Health Care Reform on the Future Supply and Demand for Physician
https://www.aamc.org/download/158076/data/updated_projections_through_20to continue practicing medicine through 2013. The remain-
ing 16% plan to transition to part-time, retire, or leave
medicine, or they are considering doing so (Fig. 23) (63).
Fourteen percent said they will most likely retire or leave
medicine within the next 5 years. Thirty-four percent will
do so within the next 10 years. Specialists reported the
following (63): oncologists and hematologists, 57% said
they would retire by 2022; otolaryngologists, 49% said they
would retire in the next decade; general surgeons, 49% said
they would retire by 2022; cardiologists, 45% said they
would retire in the next decade; and urologists, 42% said
they would retire by 2022.
Cardiovascular workforce. The ACC and the Lewin
Group’s 2009 workforce study (Fig. 24) found that a
significant shortage of cardiologists working in the United
States exists (Fig. 25), and this shortage is projected to worsen
State Physician Workforce Data Book. November 2011.
atient Care, 2008 to 2025
internal medicine, family medicine or pediatrics in the AMA Masterfile.
. Source: Association of American Medical Colleges.
ated Projections Through 2025. June 2010. Available at:
.10
2011e in P
ted as
cialties
s: Upd
25.pdf
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demands of physician lifestyle, demographics, technological
advances, healthcare reform, and economic growth (68).
If various measures, including an increase in fellowship
training and more efficient use of nonphysician practitio-
Figure 23 Physician Career Plans, Jackson Healthcare 2012 P
Source: Jackson Healthcare (63).
Figure 24 Cardiologists by Subspecialty, 2008 (n  25,901)
Source: The Lewin Group, Inc. and Association of American Medical Colleges (69).ners, are not taken, general cardiology may experience a
shortage of 15,000 practitioners by 2025 (Fig. 26). Even
with proactive measures taken, it is still projected the field
will be approximately 8,000 practitioners short of general
cardiology needs. Projections also indicate that by 2025,
interventional cardiology will still be short of approximately
2,000 physicians, equal to the current shortage (68).
Current shortages of pediatric cardiologists and cardiac
electrophysiologists are expected to be eliminated by 2025 (69).
Cardiovascular workforce growth modest. Current growth in
the cardiovascular workforce is moderate relative to the overall
physician workforce. Between 1995 and 2007, there was a
19.2% increase in cardiologists compared with a 28.6% increase
in all physicians. Increases in the ratio of cardiologists per
100,000 older persons were also lower than increases seen
for physicians overall (70).
A disparity exists in the geographic distribution of cardi-
ologists, with a lower cardiologist ratio per 100,000 older
persons in the western regions of the United States (Fig. 27)
(70). In a national survey of rural hospitals, 35% reported a
shortage of cardiologists. The region with the highest
reported need for cardiologists was the southeast region
followed by the southwest region (Fig. 28) (71).
The United States will also be short of approximately
2,000 cardiothoracic surgeons by 2030 (72). The AHA
similarly found that the need for cardiothoracic surgeons
will increase by 46% from now until 2025, whereas the
active supply of cardiothoracic surgeons is projected to
decline by 21% (73).
Retirement and workforce supply. Retirement rates will
affect the supply of cardiologists in the near future. Cur-
rently, 43% of general cardiologists, 31% of pediatric cardi-
ian Surveyhysicologists, and 21% of interventional cardiologists are over the
S22 Laslett et al. JACC Vol. 60 Suppl S, No. 25, 2012
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currently over the age of 55 years as well, and many are
expected to retire in the next 10 years (73).
More than one-half of cardiologists today are still clini-
cally active in some fashion, but failing health, professional
dissatisfaction, and inadequate compensation often contrib-
ute to early retirement. With increasing regulation in
medicine—including the need to undergo recertification—
additional influences may also factor into a cardiologist’s
decision to retire early.
Economic pressures may force some older cardiologists
to prolong their career. Alternatively, a growing number
of physicians may simply reduce the number of hours
Figure 25 Excess Demand for Cardiologists by Subspecialty, 2
Light teal  excess demand; dark teal  current supply. Source: The Lewin Grou
Figure 26 Baseline Supply and Demand for FTE General Cardio
Red  demand (baseline); purple  supply (baseline); green  demand with inco
Source: The Lewin Group, Inc., and Association of American Medical Colleges (69worked, all of which can influence projected workforce
shortages (68).
Medical school enrollment. More than 690,000 first-time
and reapplying applicants tried to enroll in U.S. medical
schools in 2011 to 2012. Of these, 32,000 were first-time
applicants, up by 2.6% from the previous year. The Asso-
ciation of American Medical Colleges also predicts that
first-year medical school enrollment will surpass 20,000 in
2014 to 2015, and that by the year 2018, enrollment will
increase by 30% compared to 2002 and 2003 (74).
First-year enrollment in Doctor of Osteopathic Medicine
(DO) programs is expected to double by 2014 to 2015
compared with 2002. Combined, MD and DO enrollment
, and Association of American Medical Colleges (69).
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levels seen in 2002 to 2003 (Table 12).
Over the last 5 academic years, the number of cardiology
programs and the fellows they train has increased in the
fields of cardiology, interventional cardiology, and pediatric
cardiology. Table 13 displays the increasing number of these
fellows for each academic year. Conversely, a decrease was
seen in the number of fellows in thoracic surgery and cardiac
electrophysiology during this same period (75).
Women in cardiovascular medicine. Unlike medicine
overall, women currently make up only a small proportion of
all cardiologists. However, this may be changing, as repre-
sentation of women in subspecialty training in cardiology
has almost doubled in the past 10 years from 10% in 1996
to 18% in 2004.68 In 2008, women accounted for 29.0% of
ediatric cardiologists, 12.1% of general cardiologists, 9.3%
Figure 27 Ratio of Cardiologists to 100,000 People Ages 65 Y
Source: Aneja et al. (70).
Figure 28 Rural Hospital CEO Reponses Regarding Need for Sp
National Rural Chief Executive Officer (CEO) Survey, 2008. We wish the response
rate of 34.4%) , but it is difficult to get even rural hospital CEOs to respond to sur
ral characteristics would be important related to assessing need for cardiologist in
percents we report are based on CEO perceptions/responses. Source: MacDowellf cardiac electrophysiologists, and 3.4% of interventional
ardiologists (Fig. 29) (69). Overall, women accounted for
3% of medical residents in 2010 to 2011; however, the
roportion of women among cardiovascular trainees was
ignificantly smaller (Fig. 30) (75).
inorities in the cardiovascular workforce. Approxi-
ately 30% of the population in the United States is either
ispanic or African American (76), but minorities, includ-
ng black, Hispanic, and Native Americans, account for only
% of practicing physicians. Black and Hispanic fellows
ere slightly better represented as 13% of internal medicine
esidents and 10% of cardiology fellows in 2006 to 2007.
A higher percentage of black trainees are now in cardiology
ellowships than in other internal medicine subspecialties, but the
roportion is still lower than that for internal medicine graduates
s a whole. The proportion of Hispanics completing internal
and Older, 2007
ist Physicians in Their Community
ould have been higher to increase confidence in the findings (overall response
Of course, careful assessment of the supply/demand balance, market, and refer-
ticular rural location. You will note our comment in the limitation section that the
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cardiology. Barriers to pursuing a career in medicine for minorities
include the financial burden of paying for education as well as lack
of role models (Fig. 31) (68).
International medical graduates. Approximately 30% of
the cardiology workforce is now made up of international
medical graduates. International medical school graduates
recently accounted for 36% of general cardiology fellows,
41% of interventional cardiology fellows, 33% of cardiac
electrophysiology fellows, and 22% of pediatric cardiology
fellows (75). Unlike minority graduates, international med-
ical graduates appear to be relatively unaffected by specialty
compensation or length of training in deciding on cardi-
ology as a career (68). International medical graduates are
more likely to remain active in practice than U.S. graduates and
to work full-time to an older age, which again is likely to have
an impact on potential workforce shortages (Fig. 32).
Global workforce. In 2000, it was estimated that 1.5
million healthcare professionals from developing countries
were working in industrialized nations, to the obvious
detriment of the poorer countries in which they were
trained. Factors behind the migration of healthcare profes-
sionals are varied but include low salaries in the country of
origin, occupational safety hazards, especially in relation to
human immunodeficiency infection, inadequacy of facilities
and medicine, and a lack of post-graduate training and
continuing professional development (Fig. 33) (77).
At 45%, internal medicine has the largest percentage of
international medical graduates now participating in U.S.
training programs, but their numbers are increasing in
cardiology, and international medical graduates now make
up more than half of interventional cardiology fellows (78).
Nevertheless, it is plausible that changing conditions glob-
Medical and Osteopathic Actual and Projected First-Year EnrollmenTable 12 Medical and Osteopathic Actual and Projected First-Y
2002 2010
Enrollment Enrollment # Increase
M.D. 16,488 18,665 2,177
D.O. 3,079 5,233 2,154
Total 19,567 23,898 4,331
Source: Center for Workforce Studies. Results of the 2010 Medical School Enrollment Survey, 2
2012.
Number of Programs and Fellows by Specialty for the Past 5 AcadeTable 13 Number of Programs and Fellows by Specialty for the
2006–2007 2007–2008
Programs Fellows Programs Fe
Cardiovascular disease 174 2,300 177 2
Clinical cardiac electrophysiology 92 168 95
Interventional cardiology 128 279 130
Pediatric cardiology 48 304 49
Thoracic surgery 85 270 81
Vascular surgery 95 208 96Source: Accreditation Council for Graduate Medical Education (75).ally and in the United States may affect the future supply of
international medical graduates.
Economic conditions and increased demand for cardio-
vascular services in their home country—or a worsening
economic climate in the United States—may diminish the
attractiveness for international medical graduates to practice
in the United States. The loss of trained medical graduates
also represents a substantial economic loss to their countries
of origin, and regulations may be altered to ensure a greater
proportion of international medical graduates either do not
leave to begin with or at least return home to practice (68).
Concerns over whether care provided by physicians edu-
cated abroad differs from U.S.-trained physicians have been
expressed. One study found no differences in mortality rates
for patients with heart failure or a heart attack between the
2 care groups (79).
Nursing workforce. In 2001, the national vacancy rate for
registered nurses was 10%. Furthermore, in 15% of
hospitals, the shortage was 20% (80). Between 2001 and
008, the number of registered nurses working full time in
oth hospital and nonhospital settings increased by some
76,000, with the largest growth in FTE registered nurses
een among those between the ages of 50 and 64 years
orking in hospitals (Fig. 34). Despite this, current projec-
tions indicate there will be a shortfall of 260,000 nurses by
2025 (81).
Cardiovascular Drugs and Devices
The pharmaceutical and medical device industries are facing
several challenges created by the cost-containment effects of
healthcare reform efforts and slow economic activity, a
changing regulatory environment, and increasing pressure to
show value related to clinical outcomes (82,83).
wth, 2002, 2010, 2015 (Existing Schools)nrollment Growth, 2002, 2010, 2015 (Existing Schools)
2015
% Increase Enrollment # Increase % Increase
13% 20,181 3,693 22%
70% 6,222 3,143 102%
22% 26,403 6,836 35%
ailable at: https://www.aamc.org/download/251636/data/enrollment2011.pdf. Accessed June
Years5 Academic Years
2008–2009 2009–2010 2010–2011
Programs Fellows Programs Fellows Programs Fellows
180 2,415 180 2,444 183 2,493
97 170 96 174 98 155
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declined to between 4% and 6% in 2010 from the 7%
growth rate recorded in 2009. Other global pressures
slowing growth of pharmaceutical sales in 2010 were price
cuts in Japan—the world’s second largest market after the
United States—and cuts to publically funded health budgets
in Europe (84). The industry is also facing an unprece-
dented wave of patent expirations, leading to a projected
cumulative loss of $78 billion in worldwide sales during
2010 to 2014, with nearly half of this erosion expected to
occur due to the loss of patents in 2011 for major block-
buster drugs. (Figure 35 shows the projected replacement
atio for 2012 [85].)
The replacement ratio in a given year is the ratio of
evenue from new products (that is, those launched in the
revious 5 years) to the revenue lost from declining products
for example, due to generic competition). This ratio is a
easure of research and development sufficiency; a ratio of
1 reflects a failure to replace former successful products
ith new revenue drivers. The data (86) are based on each
ompany’s major prescription drug portfolio (the collection
f branded drugs, each of which is projected to achieve at
east $500 million in annual sales) and were compiled before
he mergers of Pfizer and Wyeth, and Merck and Schering-
lough.
Growth in emerging international markets such as China
nd Brazil will likely offset the generic competition for many
f the world’s top selling drugs. In 2014, global pharma-
eutical sales are projected to approach $1.1 trillion as
rug sales in emerging markets are expected to grow by
p to 17% (84).
The growth of generic drugs has been beneficial to the
onsumer, allowing them more access to treatment options
nd also reducing costs to the system. An IMS analysis
ound the following related to the use of generics in the
nited States: the use of generic prescription drugs in
lace of their brand name counterparts saved the U.S.
Figure 29 Cardiologists by Specialty and Sex, 2008
Dark blue bars  males; purple bars  females. Source: The Lewin Group, Inc.,
and Association of American Medical Colleges (69).ealthcare system approximately $931 billion over thepast decade (2001 through 2010) (Fig. 36); in 2010,
generic use generated $158 billion in savings; and savings
from newer generic medicines—those that have entered
the market since 2001—continue to increase and account for
slightly more than one-third of the total savings (Fig. 36) (87).
Within the cardiovascular medicine market, the top drugs
in use have come off patent. At the end of 2011, Pfizer stood
to lose $10 billion a year when its patent expired on
atorvastatin (Lipitor, the world’s top-selling drug) (85). The
combination of extended-release niacin plus simvastatin
(Simcor) as well as fenofibric acid (Trilipix) similarly lost
patent protection in 2011. Patent protection also expired on
clopidogrel (Plavix) in 2012. In 2010, sales of clopidogrel in
the United States alone were $6 billion (88). Virtually all
of the most widely used angiotensin-II receptor antagonists,
including losartan (Cozaar/Hyzaar), irbesartan (Avapro),
candesartan (Atacand), and valsartan (Diovan), have either
already lost or will soon lose patent protection in the United
States (89). Table 14 displays key cardiovascular-related
atent expirations along with prior patent year sales.
Despite the revenue loss noted and large demand for new
rugs, and the projection of heart disease and stroke as the
eading cause of death through 2030 (90), there are only
pproximately 150 new cardiovascular drugs currently
products outlined in Fig. 37) under development compared
ith some 700 new drugs in development for the treatment
f cancer (91).
Additionally, the number CVD-related new molecular
ntities approved by the Food and Drug Administration
FDA) has declined since 1999, possibly resulting from
educed investment by the industry. This decline is repre-
ented in Table 15 (92). In response to the slowing pace of
ew drug development from industry, the National Insti-
Figure 30 Trainees by Subspecialty and Sex, 2010 to 2011
Dark blue bars  males; purple bars  females. Number of programs and res-
idents by academic year and specialty and subspecialty, 2010. Source: Accred-
itation Council for Graduate Medical Education (75).
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drug development center be established at the agency (93).
It should be noted that the FDA has approved fewer
and fewer drugs overall, not just in CVD, whereas
spending on industry-wide research and development has
nearly doubled over the past decade to $45 billion a year
(94). Figure 38 displays the increasing research and
development expenditures for both members of the Phar-
maceutical Research and Manufacturers of America and
the industry from 1995 to 2010.
Medical devices. Lucintel (a market research firm) projects
the global cardiovascular device market will reach an esti-
Figure 31 Minority Graduation Trends in
U.S. Medical Schools, 1977 to 2008
Solid line  black; dashed line  Hispanic; broken line  Asian American;
dash-dotted line  American Indian. Source: Sullivan LW, Suez Mittman I.
State of diversity in the health professions a century after Flexner. Acad Med
2010;85:193–6.
Figure 32 Percentage of International Medical Graduate Resid
Blue  cardiovascular disease; red  clinical cardiac electrophysiology; green 
Source: Accreditation Council for Graduate Medicine (78).mated $104 billion in 2017 with a compound annual growth
rate of 5.2% over the next 5 years (95). A recent pipeline
analysis found 114 devices from key manufacturers currently
in various phases of development (Fig. 39) (91).
Koncept Analytics projects the coronary stent market to
see growth from now through 2015 at a compound annual
growth rate of 3.7%, exceeding a total of $8 billion (96).
Fourth-generation bioabsorbable stents show the most prom-
ise. Results of 3 major trials—ISAR-TEST 3 (Prospective,
Randomized Trial of 3 Rapamycin-Eluting Stents With Dif-
ferent Polymer Coating Strategies for the Reduction of Cor-
onary Restenosis), ISAR-TEST 4, and LEADERS (Limus
Eluted From a Durable Versus Erodable Stent Coating)—
have suggested that the use of biodegradable polymer
drug-eluting stents (DES) lead to lower rates of target
lesion revascularization, stent thrombosis, and cardiac death
and heart attack than DES made of durable polymer (97).
Abbott has now initiated the ABSORB II trial in which
they will evaluate the safety, efficacy, and performance of
the ABSORB bioresorbable vascular scaffold compared
with 1 of the company’s own DES in patients with heart
disease (98).
Several other companies (Medtronic, Biotronic) have also
applied for or have received their conformance mark meet-
ing European Union safety and health requirements for
their bioabsorbable DES products (99).
Percutaneous devices, including those used to replace
aortic and repair mitral valves, entered the U.S. market in
2011 and are projected to account for $1.3 billion of the
projected $4.4 billion U.S. cardiovascular surgery market
by 2017 (100). Two-year data from Cohort A of the
PARTNER (Placement of Aortic Transcatheter Valve
Trial) study using the Edwards SAPIEN aortic valve now
show comparable mortality rates for patients with transcath-
eter aortic valve replacement (TAVR) and patients with
aortic valves replaced through open-heart surgery in high-
risk populations. At 2 years, the difference in stroke risk
between the groups became nonsignificant, although valvu-
by Cardiovascular Specialty/Subspecialty
ntional cardiology; purple  pediatric cardiology.ents,
interve
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adverse prognostic significance (101).
In Cohort B of the PARTNER trial, survival and life quality
of nonoperable patients treated with TAVR were significantly
improved compared with patients treated with medical man-
agement only, and readmissions were fewer (102).
Implantation of the Medtronic CoreValve prosthesis was
also recently found to be relatively safe as used in a
“real-world” clinical population and was associated with an
improvement in hemodynamics at 6-month follow-up (97).
Other percutaneous devices include the Evalve Mitra-
Clip, which permits double-orifice repair of mitral regurgi-
tation. The Cardiac Dimensions Carrilon system, the Ed-
Figure 33 Global Distribution of Physician Workforce (per 10,0
Source: World Health Statistics 2010, World Health Organization, 2010.
Figure 34 Growth in Employment of FTE RNs, by Major Employ
FTE  full-time equivalent; RN  registered nurse. Source: Buerhaus et al. (81).wards Monarc system, and the Viacor PTMA system are all
indirect coronary sinus devices that have been cited for
simplicity and ease of use, whereas the Mitralign percuta-
neous annuloplasty system, as well as the Guided Delivery
System, facilitate direct implantation of a device into the
mitral annulus and may overcome limitations of the indirect
coronary sinus approach.
In contrast, a substantial unmet need remains for medical
devices for pediatric interventional cardiology, and off-label
use of approved devices is routine in pediatric medicine.
Specifically, a study showed that during a 3-year period,
some 595 transcatheter interventions were done in approx-
imately 473 pediatric patients, median age 4.1 years. Off-
opulation), 2000 to 2009
Sector, Age, and U.S.- and Foreign-Born Status, 2001 to 200800 Pment
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of stent implantations, 78% of balloon dilations, and 29% of
coil embolizations (103).
FDA approval. Review times for drugs and biologics
increased by 28% from 2003 to 2008, whereas clearance
times for medical devices slowed by 40% over roughly the
same period. Premarket approval times have lengthened by
75% (104).
Figure 35 Projected Replacement Ratio, 2012
Orange bars  2007 replacement ratio; red bars  projected 2012 replacement
Figure 36 Savings ($ in Billions)
Due to Generic Drug Use by Year
Source: Generic Pharmaceutical Association (87).According to 1 study, companies brought products to
patients faster and at a much lower cost in Europe than in
the United States. In fact, for low- and moderate-risk
devices, it took companies 3 months to 2 years longer to
navigate the FDA for clearance or approval than it did for
similar approval from European regulators; for higher risk
devices, the process took 5 times as long in the United
States as it did in Europe. There is as yet no evidence that
patient safety in Europe has been compromised by a more
efficient approval process (105).
Unlike prescription drugs, medical devices are reviewed
by the FDA using 2 standards—pre-market approval, which
requires clinical testing and inspections, or the so-called
“510(k)” process, which requires the device be similar to an
ource: Harrison (85).
Cardiovascular Disease-RelatedP tent Expirations EN EF 90Table 14 Cardiovascul r Disease-RelatedPatent Expirations ENREF 90
Drug Company Patent Expiration
U.S. Sales in Yr Before
Patent Expiration
($ Millions)
Avapro BMS/sanofi 3/12 $281
Plavix BMS/sanofi 5/12 $6,895
Diovan Novartis 9/12 $2,333
Atacand AZ/Takeda 12/12 $110
Integrilin Merck 11/14 $288*
Benicar Sankyo 4/16 $1,066†ratio. S*Projections for 2013. †Projections for 2015. Source: Access Communications (91).
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device recalls from 2005 to 2009, it was determined that 113
recalls during this interval could cause serious health prob-
lems or death (106). Only 19% of these devices had been
approved through the pre-marketing process, whereas 71%
were cleared through the 510(k) process. Seven percent were
exempt from any FDA regulation (107).
These findings suggest that those medical devices recalled
for life-threatening or very serious hazards in this review
were originally cleared for the market using the less strin-
gent 510(k) process and that there is clearly room to reform
the regulatory process to ensure patient safety. Despite a
modest increase in funding, there was no corresponding
increase in FDA approvals for drugs or devices between
2003 and 2008, as indicated in Table 16.
The FDA is taking steps to reduce approval times for
drugs and devices, among them a streamlining of the review
process for lower risk medical devices, increasing the effi-
Figure 37 CV Pipeline Products by ACC-Defined Core Pathway
Blue  Phase II; red  Phase III; green  Registration. ACC  American College
CV  cardiovascular. Source: Access Communications (91).
Cardiovascular Disease-Related New Molecular Entities Approved bTable 15 Cardiovascular Disease-Related New Molecular Entiti
1996 1997 1998 1999 2000 2001
NME* 45 41 43 36 26 30
CVD related NMEs N/A N/A N/A 3 4 4
% CVD related NMEs to
total NMEs
N/A N/A N/A 8.3 15.3 13.3
*2004 to 2010 represent applications for new molecular entities (NMEs) filed under New Drug App
to 2003 represent NMEs but not therapeutic biologics. Source: Mehta (92).
CVD  cardiovascular disease.ciency and transparency of the review process, and estab-
lishing a new Center Science Council made up of senior
FDA experts to ensure timely and consistent decision-
making. The FDA and CMS are also considering a joint
plan for overlapping evaluation of pre-market medical
products to shorten the time it takes for newly approved
medical products to be covered by third-party payers (107).
ost-market surveillance. Post-market surveillance of
edical devices is done passively, meaning that the FDA
elies on voluntary reporting of adverse events. As a result,
he detection, analysis, and recall for potentially dangerous
evices can be slow because of not having an accurate
stimate of the adverse impact of a device. Devices like the
iata and Riata ST implantable cardioverter-defibrillator
eads, which are prone to high-voltage failure, were not
ecalled until after their widespread use (108). Although the
ead was pulled from the market in 2010 and recalled by the
DA in December of 2011,79,000 patients in the United
hase of Development
diology; ACS  acute coronary syndrome; CAD  coronary artery disease;
Food and Drug Administrationproved by the Food and Drug Administration
Year
02 2003 2004 2005 2006 2007 2008 2009 2010
2 26 32 38 26 35 34 37 23
5 1 1 0 1 3 2 3 1
2.7 3.8 3.1 0 3.8 8.5 5.8 8.1 4.3
s (NDAs) and therapeutic biologics filed under Original Biologic License Applications (BLAs). 2001and P
of Cary thees Ap
20
2
2
lication
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surveillance, Congress and the FDA are working to utilize
data from EHR, claims data, and clinical registries through
the Sentinel Initiative to receive more accurate information
(110).
Another major effort to improve market surveillance is
the Medical Device Epidemiology Network Initiative.
This initiative promotes public–private partnerships to
collect and share information about devices after they are
marketed to ensure patient safety. The partnerships are
currently exploring more novel methodologies to study
Figure 38 Pharmaceutical Companies Have Spent More on Res
But Have Discovered Fewer Novel Drugs That Gain F
FDA  Food and Drug Administration; n/a  not available; PhrMa  Pharmaceutic
Figure 39 CV Devices in Development
by Key Manufacturers by Category
Key device manufacturers were defined as those with the largest presence in
the cardiovascular (CV) device segment with active pipelines (includes
Medtronic, Boston Scientific, St. Jude Medical, Edwards Lifescience, C.R. Bard,
Sorin, Cordis, Abbot Vascular, Coviden, GE Healthcare, Philips, Siemens,
Toshiba). Blue  in early development; red  in clinical trials; green  in
approval process. Source: Access Communications (91).medical devices to track adverse events and improve
patient outcomes (111).
One of the major obstacles to surveillance is that medical
device identification is not standardized across hospital
systems, manufacturers, and distributions. To remedy this,
the FDA intends to use a unique device identification
system in the upcoming years to identify device failure rates
(112). The Sentinel Assurance for Effective Devices Act of
2012 was submitted to Congress in May to establish a
system to identify and analyze adverse events among med-
ical devices (113). The FDA has proposed the unique device
identification system rollout to begin in 2013 for implanta-
tions and other devices that support human life, such as
TAVR, pacemakers, and defibrillators. The rollout for
equipment such as radiography, pumps, and surgical drapes
is said to begin in 2015 (114).
New methods of post-market surveillance. Professional
associations and the CMS have begun collaborating to
coordinate clinical registries and other relevant databases to
track the safety of devices and procedures to enhance post-
market surveillance. One example of this collaboration is the
transcatheter valve therapy registry that tracks patients under-
going TAVR. Soon after the Edwards SAPIEN transcath-
eter heart valve was approved by the FDA in 2011, 2
professional associations (the Society of Thoracic Sur-
geons and ACC) launched the transcatheter valve therapy
h and Development Over Time,
pproval
earch and Manufacturers of America. Source: Wilson (94).
New Drug and Device Approvals byU.S. Food rug Administration, 2003–2008Table 16 New Drug a d Device Approvals byU.S. Food and Drug Administration, 2003–2008
Category 2003 2004 2005 2006 2007 2008
New molecular entities 21 31 18 18 16 17
Biologic license
applications*
5 2 4 2 3
f41Device premarket
application
approvals†
33 46 32 38 25 25
*The Food and Drug Administration reported biologic license approvals beginning in 2004.earc
DA A
al Res†Numbers include instruments, implantables, patient monitoring, diagnostic devices, and in vitro
tests. Source: Dorsey et al. (130).
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patients who undergo TAVR (115). Information from
the transcatheter valve therapy registry is linked to the
Social Security Death Master File as well as to other
CMS databases to track the long-term health outcomes
and can be utilized by the FDA for post-market surveil-
lance (116).
Similar registries have also been mandated by CMS for
coverage determinations and tracking of patient out-
comes. For example, patients receiving an implantable
cardioverter-debrillator are required to participate in the
implantable cardioverter-debrillator registry sponsored by
Figure 40 Number of Medical Schools With Perfect Scores in E
Red bars  2008; blue bars  2009; green bars  2010. Source: American Med
Figure 41 Effect of Physician Payment Disclosure Laws on Pre
SSRI  selective serotonin reuptake inhibitor. Source: Arch Intern Med 2012;172the Heart Rhythm Society and ACCF for Medicare
coverage. Registries operated by professional societies for
devices with significant expense and risk are gaining value
because CMS and other payers are interested in measur-
ing patient outcomes (117).
Additionally, 4 professional associations (American As-
sociation for Thoracic Surgery, ACCF, Society for Cardio-
vascular Angiography and Interventions, and The Society of
Thoracic Surgeons) collaborated to publish an Expert Con-
sensus Document on TAVR to advise payers, providers, and
other stake holders on safely incorporating TAVR into their
practice (116). To ensure national standards for patients
Assessed Domain, 2010
ssociation.
ing and Expendituresa
21; doi:10.1001/archinternmed.2012.1210.ach
ical Ascrib
:819–
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ysis was requested of CMS. In May 2012, CMS approved
reimbursement for providers that perform TAVR given the
following conditions are met: the valve and implantation
system have FDA premarket approval; 2 cardiac surgeons
independently evaluate the patient; the patient is under the
care of a multidisciplinary heart team at a hospital qualified
to perform TAVR; both the interventional cardiologist and
cardiac surgeons are involved with the implantation; and the
heart team and hospital participate in a TAVR registry
(118).
Relationships With Industry
The Physician Payment Sunshine Act, a section of the
ACA, was created to disclose payments to physicians from
private industry (pharmaceutical and medical device com-
panies). It was scheduled to be implemented in January 1,
2012, but CMS delayed the implementation to 2013 to
address logistical issues and data accuracy (119).
A number of academic medical centers and states have
implemented new policies that more strictly manage rela-
tionships between physicians and industry. For example, in
2010, Harvard’s Partners Healthcare capped payments its
physicians can receive for serving on corporate boards at
$5,000 a day. In the same year, Massachusetts required
conflict-of-interest (COI) policies be posted on its public
health website, and an increasing number of universities
have placed a ban on gifts from pharmaceutical compa-
nies (120).
Simultaneously, a number of pharmaceutical companies
including GlaxoSmithKline, Lilly, Merck, and Cephalon
have been disclosing payments to physicians on their com-
pany websites (120). Newly proposed regulations would also
compel researchers funded by the NIH to disclose their
financial ties to industry and lower the threshold at which a
Figure 42 Expected Change in Investment in Aggregate Spend
Reporting and Disclosure Compliance, 2010 to 2012
Blue bars  2010; red bars  2011; green bars  2012. Source: Pelletier (125).researcher’s financial interest requires disclosure to $5,000.Institutions would also be required to create plans to
manage all identified financial COIs under the same pro-
posed rules, and every publicly funded institution would
similarly have to disclose all significant COIs online. Inves-
tigators, in turn, would be required to undergo COI training
before engaging in publicly funded research, and training
would be required every 2 years thereafter (121).
Most medical schools in the United States have imple-
mented COI policies governing industry interactions at the
schools. As a measurement of these interactions, the Amer-
ican Medical Student Association developed a PharmFree
Scorecard that grades medical schools according to their
COI policies (122). In 2012, 102 of 152 medical schools in
the United States received a grade A or grade B for their
COI polices, up from 79 in the previous year. The trends of
schools achieving perfect grades on the PharmFree Score-
card is displayed in Figure 40 (123). Furthermore, one-third
of U.S. medical schools incorporated COI policies into their
curriculum (120).
A recent study of physician prescribing habits in Maine
and West Virginia, which both enacted payment-disclosure
legislation in 2004, found that, in Maine, prescribing of
branded selective serotonin reuptake inhibitors was actually
3.7 percentage points higher than in New Hampshire, a
state that did not enact them. The prescribing patterns for
statins showed little difference across states with the enacted
legislation (Maine and West Virginia) compared to those
without legislation (Kentucky and Delaware) (Fig. 41)
(124).
Responding to this increased pressure for transparency, life
science executives (pharmaceutical, biotech, and medical device
companies) expect to increase their investment in aggregate
Figure 43 Funding for Biomedical
Research by Source, 2003 to 2007
Light blue  medical device firms; medium blue  biotechnology firms; deep
blue  pharmaceutical firms; black  private funds; light gray  state and
local government; medium gray  federal support other than National Insti-
tutes of Health; and dark gray  National Institutes of Health. Source: Dorsey
et al (130).
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(Fig. 42). The expected increase is partly due to federal
regulations and the trend of global transparency.
Additionally, 88% of attendees surveyed at the Fourth
Annual Life Sciences Meeting Management Forum said
they already had a system in place to track physician
payments, and 76% were already testing their systems (125).
Funding for Biomedical Research
For the 2013 fiscal year, $140.8 billion of President
Obama’s proposed $3.8 trillion budget has been allocated to
research and development (126,127). Funding recommen-
dations for federal research for the fiscal year 2013 include
$30.7 billion to the NIH (128), $7.4 billion to the National
Science Foundation, and $583 million to the Department of
Veterans Affairs medical and prosthetics research program
(129).
The NIH is the largest federal contributor to biomedical
research, accounting for 84% of total federal funding in
2007 (130,131). In 2011, the NIH allocated a total of $2.1
billion to cardiovascular research. More specifically, $1.2
billion was allocated to heart disease research, $317 million
Figure 44 Open Phase III Clinical Trials Globally in 2007 by the
(A) Sites. (B) Trials. Source: Glickman et al. (136).to stroke research, and $437 million to coronary heart
disease research (131).
The National Heart, Lung and Blood Institute, an
institute within the NIH, has been funding the Cardiovas-
cular Research Network (CVRN), which brings together
researchers and databases from 15 integrated health plan
members of the NIH health maintenance organization
research. This network has access to the EHR of 11
illion patients, and the electronic database of the CVRN
ffers significant potential for a broad array of research
pportunities (132).
The NIH awarded $13 million to the CVRN for
esearch regarding heart failure, atrial fibrillation, and CVD
urveillance (133). A $7.2 million grant from the National
eart, Lung, and Blood Institute is supporting the devel-
pment of an integrated surveillance system that will pro-
ide comprehensive information regarding the burden of
VD in the United States (131).
From 2003 to 2007, funding for biomedical research
ncreased by 14%, to a total of $101.1 billion in 2007, a
onsiderably higher annual growth rate than the 7.8%
rowth reported for the years 1994 and 2003. The growth in
Largest U.S. Pharmaceutical Companies20
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Source: Mays and Smith (138).Figure 46 Age-Adjusted Death Rates for Cardiovascular Disease, Coronary Heart Disease, and Stroke, 1980 to 2008
Blue line  all cardiovascular disease; red line  coronary heart disease; and green line  stroke. ICD  International Classification of Diseases. Source: National
Institutes of Health, National Heart, Lung and Blood Institute. Morbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Available at:
http://www.nhlbi.nih.gov/resources/docs/2012_ChartBook_508.pdf.
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Industry was the largest source of funding in 2007, account-
ing for 58% of the total, followed by the federal government,
which accounted for 33%. Taken together, support from
pharmaceutical, biotechnology, and medical device compa-
nies increased by 25% (adjusted for inflation) from 2003 to
2007, where it peaked at $58.6 billion (130).
The biopharmaceutical industry spent an estimated $67.4
billion on research and development in 2010. Between 2000
and 2010, 333 drugs or biologics were approved by the
FDA. Each drug takes 10 to 15 years to be developed and
approved, and on average costs approximately $1.3 billion
(134).
Although the pharmaceutical industry is sponsoring more
research and development, more clinical trials are moving to
developing countries (135). A study from the New England
Journal of Medicine noted that the shift is due to the more
cost intensive and complex regulatory environments in the
United States and Western Europe. The funding required
for clinical trials in the United States often exceeds the
federal funding allotted for biomedical research. Figure 44
displays the open phase 3 clinical trials by the number of
sites and trials by the top 20 largest U.S. pharmaceutical
companies in 2007. The FDA reported that the number of
regulated investigations conducted outside of the United
States has grown by 15% annually.
Deaths from Coronary Heart Disease That Were Prevented or PostponTable 17 Deaths from Coronary Heart Disease That Were Prevent
Absolute Level of
Risk Factor‡
Change in
Risk Factor
Beta Regres
Coefficient
Change i
Mortality Ra1980 2000
Absolute
Change
Relative
Change
(%)Risk Factor†
Smoking prevalence (%) 36.3 24.6 11.7 32.2
Men
Women
Systolic blood pressure
(mm Hg)
129.0 123.9 5.1 4.0
Men 0.0334
Women 0.0413
Total cholesterol
(mmol/l)
5.67 5.33 0.34 6.1
Men 0.9458
Women 0.9121
Physical inactivity (%) 29.6 27.3 2.3 7.8 —
Men
Women
BMI 25.6 28.2 2.6 10.1
Men 0.0297
Women 0.0297
Diabetes prevalence (%) 6.5 9.4 2.9 44.2 —
Men
Women
Total risk factors
*Percentages may not sum to 100 because of rounding. BMI denotes body-mass index (the weig
milligrams per deciliter, divide by 0.02586. Data sources are described in the Supplementary Appe
exclude patients receiving treatment for hypertension, and for total cholesterol, the numbers exclu
physical inactivity, which are from the Behavioral Risk Factor Surveillance System. §The change in the m
BMI  body mass index.There are concerns regarding clinical trials conducted
abroad. One concern is ethical oversight. In a study of
researchers in developing countries, 56% reported that their
studies were reviewed by a local institutional review board or
ministry of health. Further concerns regarding the general-
izability of the results have been discussed by the FDA
relating to potential genetic and socioenvironmental factors
that affect treatment efficacy among patient populations in
developing countries (Fig. 45) (136).
Cardiovascular Prevention
Cardiovascular prevention efforts are receiving growing
attention in an effort to offset the increasing burden of
disease and to stem rising healthcare costs. Federal efforts,
public agencies, and employers are developing strategies
addressing risk factors associated with CVD.
The debate continues around which approach has had the
greatest impact on reducing mortality from coronary heart
disease: better control of cardiovascular risk factors or the
use of medical interventions (137). An analysis of the effect
of increased public health spending on mortality found that
public health spending is not significantly associated with
overall mortality; however, increased public health spending
correlated with lower heart disease-related mortality rates
(138).
a Result of Changes in Population Risk FactorsPostponed as a Result of Changes in Population Risk Factors
Relative
Risk
Deaths Prevented or Postponed
Best
Estimate
Minimum
Estimate
Maximum
Estimate
Best
Estimate
Minimum
Estimate
Maximum
Estimate
No. of Deaths Percent of Total Reduction
39,925 34,955 52,435 11.7 10.2 15.3
2.52
2.14
68,800 53,730 105,060 20.1 15.7 30.7
82,830 58,455 95,570 24.2 17.1 28.0
17,445 8,340 29,035 5.1 2.4 8.5
1.27
1.33
25,905 14,430 40,405 7.6 4.2 11.8
33,465 23,885 43,330 9.8 7.0 12.7
1.93
2.59
149,635 117,165 198,360 43.8 34.3 58.0
ilograms divided by the square of the height in meters). To convert the values for cholesterol to
he total adult population in 1980 was 177,745,055. For systolic pressure, the numbers of deaths
ents receiving statins. ‡Data are from the National Center for Health Statistics, except for data oned ased or
sion
for
n
te§
ht in k
ndix. †T
de patiortality rate per unit of measurement for the risk factor is shown. Source: Ford et al. (140).
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reports that the CVD age-adjusted mortality rate dropped
from 543.7 per 100,000 in 1980 to 244.8 per 100,000 in
2008. Figure 46 displays the decline of age-adjusted mor-
tality rates from 1980 to 2008 for CVD, coronary heart
disease, and stroke with a designation of the transition from
International Classification of Disease-Ninth Edition (in
italics) (ICD-9) to ICD-10 mortality coding in 1999 (139).
Figure 47 Characteristics of Current Risk Estimation Systems
ATP  Adult Treatment Panel; AUROC  area under receiver-operating characteris
cardiovascular disease; Hb  hemoglobin; HDL  high-density lipoprotein; hs-CRP
lipoprotein; MI  myocardial infarction; NCEP  National Cholesterol Education Pr
ence citations throughout this figure related to the original source. Source: CoonePrevious studies found that the decline for coronary heartdisease from 1980 to 2000 was attributed fairly equally to
improvements in treatment (47%) and risk factor control
(44%) (140).
Ford et al. (140) modeled the effects of risk factor control,
finding that reductions in major risk factors may have
accounted for approximately 44% of the decrease in deaths
from coronary heart disease from 1980 to 2000 (Table 17).
Earlier U.S. studies suggested a similar contribution of
e; BMI  body mass index; CCS  Canadian Cardiovascular Society; CVD 
h-sensitivity C-reactive protein; JBS  Joint British Societies; LDL  low-density
; SBP  systolic blood pressure; WHO  World Health Organization. The refer-
. (152).tic curv
 hig
ogram
y et alapproximately 54% of the reduction in deaths between 1968
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1990 (142). The investigators note that “most of the
changes in treatments and risk factors between 1980 and
2000 led to reductions in deaths from coronary heart disease
with 2 major exceptions: increases in BMI accounted overall
for about 26,000 additional deaths from coronary heart
disease in 2000 and increases in the prevalence of diabetes
for about 33,500 additional deaths” (140).
Despite mixed evidence on the optimal mix of prevention
approaches, it is clear that they each have positive effects on
CVD. Thus, the ACA allocated $15 billion in federal
funding to prevention efforts related to CVD (143). Under
these provisions, an estimated 54 million Americans will
receive preventive services. Reimbursement rates will also be
increased for preventive services for Medicare and Medicaid
Figure 47 Continuedbeneficiaries (144).The U.S. Preventive Services Task Force developed the
following CVD-specific recommendations that will be cov-
ered under Medicare, Medicaid, and non-grandfathered
insurance plans (plans established after March 23, 2010):
• Aspirin to prevent CVD in men (ages 45 to 79 years)
and women (ages 55 to 79 years)
• High blood pressure screening for all adults
• Cholesterol screening for men (over age 35 years) and
women (over age 45 years)
• Type 2 diabetes screening for adults with sustained
high blood pressure (135/80 mm Hg)
• Healthy diet counseling (intensive behavioral dietary
counseling) for adults with risk factors for CVD
• Obesity screening and counseling for adults and children(behavioral interventions to promote weight loss)
S38 Laslett et al. JACC Vol. 60 Suppl S, No. 25, 2012
The Worldwide Environment of Cardiovascular Disease December 25, 2012:S1–S49• Tobacco use counseling for pregnant and nonpregnant
adults (counseling varies by status) (145).
Non-grandfathered insurance plans are required to fully
cover specified preventive health services on the premise
that people are more likely to take advantage of preventive
care practices if they are not responsible for copays or other
deductibles (146,145).
Employers have shown interest in addressing risk factors at
the workplace. Studies of workplace wellness programs suggest
Figure 48 Age-Adjusted Awareness, Treatment, and Control of
United States, 2007 to 2010
Blue bars  2007 to 2008; green bars  2009 to 2010. Source: Yoon et al. (15
Figure 49 Trends in Percentage of Adults Age 20 Years and Ol
HP  Healthy People. Source: Carroll et al. (160).that healthcare costs are reduced and health outcomes improve
when risk factors are reduced (147).
Risk estimation frameworks. Cooney et al. (148–151)
report that all current CVD prevention guidelines stress the
need to consider the likely impact of all risk factors before
making clinical management decisions and, in most cases, to
recommend a system of evaluating combined risk factor
effects. They go on to provide a comparison of the Framing-
ham system, the best known both nationally and interna-
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commonly used systems recommended by guidelines on
CVD prevention (Fig. 47) (152).
Risk factor control. HYPERTENSION. Uncontrolled hyper-
ension is the leading attributable risk factor for CVD (i.e.,
troke, myocardial infarction, heart failure, renal failure) and
ortality worldwide (153–155). Hypertension is a prevalent
ondition affecting approximately 1 in 3 adults in the United
tates (28.6%) (Fig. 48) (156). Among adults with hyper-
ension in 2009 to 2010, 81.9% were aware of their
ypertension, and 76.4% reported currently taking pre-
cribed medication to lower their blood pressure (Fig. 48).
Figure 50 Percentage of Adults Age 20 Years and Older With H
United States, 2009 to 2010
Green bars  all race and ethnicity groups; dark blue bars  non-Hispanic white;
Source: Carroll et al. (160).
Figure 51 Statin Drug Use in Past 30 Days Among Adults >45
Statin drug use in the past 30 days among adults 45 years of age, by sex (men
(gold bars), 1999 to 2002 (teal bars), and 2005 to 2008 (purple bars). *Estimahere was no change from 2007 to 2008 in the awareness
nd treatment of hypertension (Fig. 48) (156).
Resistant hypertension, defined as blood pressure that remains
bove goal (140/90 mm Hg) despite the concurrent use of 3
different classes of antihypertensive agents at optimal doses,
including a diuretic) (155), is estimated to affect approximately
12% of the population according to analysis of National Health
and Nutrition Examination Survey data between 2003 and
2006 (157). As the U.S. population ages and the incidence
and prevalence of obesity rises, the prevalence of resistant
hypertension is projected to increase to 15% to 30%
(154,158).
Total Cholesterol, by Sex, Race, and Ethnicity:
ray bars  non-Hispanic black; and medium gray bars  Hispanic.
rs of Age, by Sex and Age
anel]; women [right panel]) and age, in United States, 1988 to 1994
considered unreliable. Source: National Center for Health Statistics (161).igh
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option for managing resistant hypertension and is currently
available in the European Union and Australia. The proce-
dure utilizes a radiofrequency catheter that is inserted into
the renal artery to disrupt the renal sympathetic nervous
system. Medtronic has developed a Symplicity catheter
system for this procedure and is the first company to receive
FDA approval to study the technique in the United States.
Catheter systems are also being developed by several other
device companies and numerous studies of this therapy are
in progress. As of August 2012, clinicaltrials.gov lists 45
studies on renal denervation: completed, 1; active, not
recruiting, 9; recruiting, 31; and not yet recruiting, 4.
Figure 52 Prevalence of Obesity Among Children and Adolescent
Dark blue bars  2 to 19 years; dark-medium blue bars  2 to 5; medium-light blue
(161).
Figure 53 Overweight and Obesity Among Adults >20 Years of
(Left panel) Men. (Right panel) Women. Source: National Center for Health StatisDYSLIPIDEMIA. There is a growing recognition that a
target-based approach to lipids may not be the best strategy
and is not strongly based on trial evidence. Not all drugs
that reduce low-density lipoprotein (LDL) have been
shown to reduce patient risk—and some have paradoxically
increased risk. Moreover, no large trial tested a target
strategy—they were trials of fixed doses of specific drugs.
Also, the benefit of statins has generally been shown to be
consistent across initial levels of LDL. As a result, some experts
are advocating statins over a target that may be reached with
a variety of drugs, including those that have not been
shown to improve outcomes. Also, some experts are
advocating a strategy to treat based on patient risk rather
s 2 to 19 Years, by Sex and Age: United States 2009 to 2010
6 to 11; light blue bars  12 to 19. Source: National Center for Health Statistics
, by Sex: United States, 1988 to 1994 Through 2007 to 2008
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on the risk not the lipid level (159).
Lipid levels among U.S. adults are declining. Between
1999 and 2000, 18.3% of men and women had high total
cholesterol count—defined as 240 mg/dl or higher. This
dropped to 13.4% in 2009 to 2010 (displayed in Fig. 49).
The U.S. Hispanic population is reported to have the
highest percentage of adults (over 20 years of age) with high
total cholesterol levels (Fig. 50) (160).
STATINS AND LDL CHOLESTEROL REDUCTION. There is
ubstantial evidence supporting the use of statin therapy
o reduce LDL cholesterol and subsequent risk of coro-
ary heart disease. From 1988 to 1994 through to 2005
nd 2008, the use of statin therapy in U.S. adults 45 years
f age increased 12-fold, from 2% to 25% (Fig. 51). The
Figure 54 Diabetes Prevalence Among Adults >20 Years of Ag
Gold bars  1988 to 1994; blue bars  2005 to 2008. Source: National Center
Figure 55 All-Cause and CVD-Related Mortality Rates (Deaths
CVD  cardiovascular disease; CI  confidence interval; DM  diabetes mellitus;ocumented decline in total cholesterol in the U.S.
opulation is likely attributable to increased use of the
tatins at least in part (161). There is, however, disagree-
ent on the use of statins for primary prevention of
oronary heart disease for persons at high-risk but who
how no symptoms (162,163).
The ACCORD (Action to Control Cardiovascular Risk in
iabetes) trial and the Fenofibrate Intervention and Event
owering in Diabetes trial found that that fenofibrate did not
educe cardiovascular morbidity or mortality over that pro-
uced by a statin alone (164). However, the ACCORD trial
nd other previous research indicated there is potential
enefit to men to include fibrate treatment for those with
levated triglycerides and low high-density lipoprotein
HDL) cholesterol after using statin therapy to reduce LDL
Age: United States, 1988 to 1994 and 2005 to 2008
alth Statistics (161).
00,000 Person-Years), by Cohort and DM Status
hazard rate ratio. Source: Gregg et al. (177).e, by
for Heper 1
HRR 
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the development of drugs that raise HDL cholesterol,
reducing LDL cholesterol at the same time.
The first version of cholesteryl ester transfer protein
inhibitors, torcetrapib, proved to cause excess deaths. A new
version, anacetrapib, has not be shown to increase the risk of
cardiovascular events, and the drug was associated with a
138% rise in HDL cholesterol and a 40% drop in LDL in
1 clinical trial (166). Based on early data, some 30,000
patients were to receive anacetrapib starting in 2011 to test
whether adding the drug to a statin further reduces mor-
bidity and mortality (167). Another version of transfer
protein inhibitors, dalcetrapib, was tested but in mid 2012
phase III clinical trials ended because it was not found to
significantly increase HDL cholesterol and lower LDL
cholesterol (168).
OBESITY. Obesity is usually defined by BMI, where
persons with a BMI of 30 kg/m2 are considered to be
bese and those with a BMI 35 kg/m2 are grade 2 obese
(161). Excess body weight is associated with excess
morbidity and mortality from CVD (169), and grade 2
obesity significantly increases mortality risk (170). From
1999 to 2000 through 2009 to 2010, the prevalence of
obesity increased from 13.8% to 15.0% among girls and
from 14% to 18.6% among boys in the United States.
Figure 52 displays the current prevalence by age group
among adolescents.
Among women in the same time period, there was an
increase in the prevalence of obesity (33.4% to 35.8%). In
1999, the prevalence of obesity in men was approximately
27.5%; 10 years later, that number had risen to 35.5%. In
terms of numbers, this means 12.5 million children, 40.6
Figure 56 Cigarette Smoking Among Students in Grades 9 to 1
United States, 1999 to 2009
(Left panel) Males. (Right panel) Females. Source: National Center for Health Stamillion women, and 37.5 million men were obese in 2009 to2010 (171,172). Figure 53 displays obesity rates among men
nd women.
DIABETES MELLITUS. Approximately 8% of the population
or 18.8 million people in the United States have been diag-
nosed with diabetes, the great majority of them with type 2
diabetes (173). Another 7 million people have undiagnosed
diabetes, and some 79 million have pre-diabetes (174).
Type 2 diabetes is also affecting younger and younger
people. It is now estimated that 215,000 children and
adolescents under the age of 20 years have diabetes (174).
The incidence of diabetes is also increasing in the United
States, in parallel with increasing obesity rates (173). By
2050, the Centers for Disease Control and Prevention
predict as many as 1 in 3 adults in the United States could
have diabetes if current trends continue (175). Figure 54
depicts the increasing prevalence of type 2 diabetes among
U.S. adults.
Approximately two-thirds of persons with diabetes die
from heart disease or stroke (173). Those with diabetes also
have triple the risk of stroke compared with persons who
have normal blood sugar levels (176). However, as the death
rates of CVD decreases for the general population, the
proportion of CVD-related deaths among diabetic patients
has decreased, as shown in Figure 55. According to Gregg
et al. (177), among diabetic adults, the CVD death rate
declined by 40%, and all-cause mortality declined by 23%
between 1997 and 2006. There was no difference in the
rates of decline in mortality between diabetic men and
women. The excess CVD mortality rate associated with
diabetes (i.e., compared with nondiabetic adults) decreased
by 60% (from 5.8 to 2.3 CVD deaths per 1,000), whereas
the excess all-cause mortality rate declined by 44% (from
d Adults >18 Years of Age, by Sex, Grade, and Age:
(161).2 an
tistics10.8 to 6.1 deaths per 1,000) (177).
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December 25, 2012:S1–S49 The Worldwide Environment of Cardiovascular DiseaseCareful glycemic control is currently considered the
cornerstone of diabetes management, and research has
shown that reaching and maintaining treatment goals can
result in a decreased risk of diabetes-related complications,
lower costs, and less healthcare utilization (174,178). The
ADA and the Academy of Clinical Endocrinology/
American Association of Clinical Endocrinologists have
published specific glycemic goals for managing adult, non-
pregnant patients with diabetes (174,179), which emphasize
the importance of an individualized approach to the man-
agement of type 2 diabetes by selecting agents and regimens
tailored to the unique needs of patients (178).
However, although there has been some recent improve-
ment in the percentage of people with diabetes who have
achieved treatment goals over the last few years (180),
Figure 57 Trends in CV Health Metrics and Associations With
The Y-axis segments shown in blue indicate range from 0 to 0.2. Source: Yang Q
“ABCS” Indicators—Comparison of 2017 Million Hearts’ Goals WitTable 18 “ABCS” Indicators—Comparison of 2017 Million Hea
Indicator Definition
Aspirin People with increased risk of CVD who take as
Blood pressure People with HTN who have controlled BP
Cholesterol People diagnosed with high cholesterol who ha
properly controlled
Smoking Decrease population of smokers
Sodium intake Decrease average sodium intake
Artificial transfat consumption Decrease amount of artificial transfat consump
*Total across all practices, year ending second quarter 2011. Source: American Heart Ass
http://www.telligenhitrec.org/c/document_library/get_file?uuidd1ff5a8f-d86c-45e1-8cac-3616ABCS aspirin for people at risk, blood pressure control, cholesterol management, and smoking cessat
INNACLE  Practice Innovation And Clinical Excellence.50% of people with diabetes achieve the ADA’s recom-
mended hemoglobin A1c goal of 7.0% (176), and 67% do
not achieve the American Association of Clinical Endocri-
nologists’ A1c goal of 6.5% (181).
SMOKING. It is estimated that 40% of all heart disease is
related to smoking (46). Smoking is also a major risk
factor for stroke, approximately doubling the risk for
ischemic stroke and increasing the risk of subarachnoid
hemorrhage by twofold to fourfold (182). Smoking rates
have been declining since the 1960s when the Surgeon
General first warned of the health effects of cigarettes. In
1965, 41.7% of adults smoked; in 2010, that number had
dropped to 19.3%. Figure 56 shows declining smoking
rates across different age groups.
use and CVD Mortality Among U.S. Adults
187).
1 PINNACLE Registry Data Submitting Practicesoals With 2011 PINNACLE Registry Data Submitting Practices
Baseline 2017 Goal
Comparable PINNACLE
Measure* SD
47% 65% 83% 15.3
46% 65% 69% NA
33% 65% 98% 2.5
19% 17% 41% 34.9
3.5 g/day 20% reduction NA NA
1% of calories/day 50% reduction NA NA
. Million Hearts Campaign and the Role of the American Heart Association. Available at:
96&groupId10309. Accessed June 2012.All-Ca
et al. (h 201rts’ G
pirin
ve it
tion
ociation
dcb394ion; BP blood pressure; CVD cardiovascular disease; HTN hypertension; NA not available;
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disease, heart failure, and nonvalvular atrial fibrillation (or any
combination of the 3), reported that 10.6% were current
smokers and 36.5% of them were former smokers (183). Another
Figure 58 Participation in Leisure-Time Aerobic and Muscle-Strength
for Adults >18 Years of Age, by Sex and Age: United Sta
(Left panel) Men. (Right panel) Women. Source: National Center for Health Statis
Figure 59 How Do Typical American Diets Compare to Recomm
AI  adequate intake level; RDA  recommended daily allowance; SoFAS  solid
Source: USDA. Choose My Plate: Guidelines. Available at: www.mypyramid.gov/gustudy found that approximately 13% of patients with coronary
artery disease were current smokers (184). Smoking has also been
shown to diminish the benefits of statins, worsen hypertension,
and contribute to CVD morbidity and mortality (185).
Activities Meeting 2008 Federal Physical Activity Guidelines
999 to 2009
61).
d Intake Levels or Limits?
nd added sugars; UL  upper limit; USDA  U.S. Department of Agriculture.
s/policydoc.pdf. Accessed June 2012.ening
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December 25, 2012:S1–S49 The Worldwide Environment of Cardiovascular DiseaseMillion Hearts Initiative. A significant public private
campaign launched in 2011 targeting cardiovascular preven-
tion is the Million Hearts Initiative, the goal of which is to
prevent 1 million cardiovascular events over the next 5 years.
Through improved management of the 4 “ABCS” indica-
tors—aspirin for people at risk, blood pressure control,
cholesterol management, and smoking cessation—the Mil-
lion Hearts Initiative hopes to reduce the current annual
heart attack and stroke rate by 10% (Table 18) (173).
The ACC is moving forward with its participation in
the Million Hearts Initiative. The College has offered
comments on the blood pressure control and lipid man-
agement measures. Concerns were raised that pushing all
patients to the 140/90 mm Hg blood pressure target may
put some at risk due to the potential for unintended
consequences, and that the lipid management measure
should not be based solely on a target LDL (100 mg/dl)
and may be too simplistic based on recent evidence.
To improve the measures, the ACC/AHA Task Force
on Performance Measures has offered to commission 1 or
more studies to compare the effectiveness of these differ-
ent measures. If the ACC/AHA/Physician Consortium
for Performance Improvement blood pressure and lipid
measures are superior to the Healthcare Effectiveness
Data and Information Set measures when used at the
physician and practice levels, then it would be demon-
strated with actual evidence of impact on clinical out-
comes of interest at the population level (186).
IDEAL CVD HEALTH BEHAVIORS. The great majority of the
population does not meet ideal cardiovascular health met-
rics, as defined by the AHA. These 7 behaviors or health
metrics include not smoking; being physically active; having
normal blood pressure, blood glucose levels, total choles-
terol, and weight; and eating a healthy diet. According to
the latest National Health and Nutrition Examination
Survey, only 1.2% of a representative sample of 44,959 U.S.
adults achieved all 7 health metrics, whereas only 8.8% of
the same cohort achieved 6 or more (187).
For the select proportion of persons who did meet 6 or more
of the AHA’s health metrics, all-cause mortality was 51%
lower than for persons who achieved 1 or fewer cardiovascular
health metrics; and CVD mortality was 76% lower for the
highest achievers versus the lowest achievers. Mortality from
ischemic heart disease was 70% lower, again in favor of the
highest health metric achievers versus the lowest.
These findings support prevention strategies aimed at
improving CVD risk factors as a highly significant way in
which to reduce morbidity and mortality caused by CVD
(173). Figure 57 depicts the differences in morbidity and
mortality according to the health metrics achieved.
INCREASE REGULAR PHYSICAL ACTIVITY. The AHA also
defines “ideal” levels of physical activity as either 150
min/week of moderate intensity activity or 75 min/week
of vigorous intensity activity or 150 min/week of moder-
ate and vigorous activity combined (173).On the same survey, 45.2% of the population achieved
ideal levels of physical activity, whereas another 22.9%
achieved AHA-defined levels of intermediate activity,
namely, 1 to 149 min/week of moderately intense activity
or the same amount of moderate and vigorous activity
combined, or 1 to 74 min/week of vigorous activity. Some
31.9% of the population reported no levels of physical
activity in 2010 (173). Figure 58 shows trends in physical
activity across different age groups out to 2009.
The prevalence of physical activity has marginally in-
creased among U.S. adults since the late 1980s (188), but
the majority of adults are still not physically active enough to
meet the guidelines for optimal health (187). Inadequate
amounts of physical activity are widely acknowledged to be
a major contributor to the rising rates of obesity in the
United States (189).
HEALTHY DIETARY CHANGES CRITICAL. The AHA mea-
ures how healthy a person’s diet is by assigning 1 point to
ach specific dietary component for a score of 0 to 5.
omponents include consumption of fruits and vegetables
4 cups a day; fish, 2 3.5-oz servings/week; fiber-rich
hole grains 3 1-oz equivalent servings per day; sodium
1,500 mg/day, and sugar-sweetened beverages 36 oz/
eek. According to National Health and Nutrition Exam-
nation Survey data, 22.3% of the population had a healthy
iet score of 2 components from 2005 to 2010, a 3.1%
ncrease from 1999 to 2004 (187). Figure 59 shows how a
ypical American diet compared with recommended intake
evels of various food components.
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APPENDIX
For a table on chronic cardiovascular conditions family of measures,
please see the online version of this article.
